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microspheres
Abstract
This thesis examines the encapsulation of an integrin-binding protein (FU19'- 
10) in poly(lactic-co-glycoiic acid) (PLGA) microspheres fabricated following a water- 
in-oil-in-water (w/o/w) emulsion solvent evaporation technique. To avoid protein 
adsorption at the water/oil interface, non-ionic surfactants such as Pluronic F68, Tween 
20, Tween 80, Triton X-100 and Igepal CA-630, were individually added to the water 
phase of the primary emulsion, and compared against model stabilisers such as 
polyvinyl alcohol (PVA) and bovine serum albumin (BSA).
The backbone integrity and biological activity of Fm9'-10 were examined by 
sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) analysis and cell-adhesion 
assay, respectively. It was found that the P-fold peptide backbone organisation was 
maintained throughout microencapsulation and that F1119'-10 promoted cell attachment 
in a concentration-dependent manner, as desired.
Physical characterisation of the microspheres showed spherical particles of 
-100 pm diameter with varying surface morphology, ranging from smooth and highly 
porous for microspheres made without non-ionic surfactants, to corrugated and 
scarcely porous for particles fabricated with non-ionic surfactants. These variations 
were attributed to the molecular interactions between surfactant and drug/PLGA. 
Examination by dynamic vapour sorption (DVS) and differential scanning calorimetry 
(DSC) of microspheres made with F1119'-10 and Triton X-100, selected due to their 
high encapsulation efficiency (48.2% ±17.2) and their low external porosity, showed 
that the small Triton X-100 molecules had infiltrated the PLGA matrix thereby 
creating additional free-volume and decreasing the glass transition temperature (Tg) of 
the polymeric microspheres. The improved capacity for molecular mobility was used 
to induce surface remodelling of these particles upon exposure to 75% relative 
humidity. Topographical images of the microspheres prepared with Triton X-100, via 
atomic force microscopy (AFM) measurements, highlighted the significant reduction 
in pore depth from 1.57 pm to 0.48 pm suggesting a degree of pore closure. In vitro 
testing confirmed the phenomenon of pore closure as the initial burst release recorded
after 4 hour incubation fell from 91% for untreated microspheres, to 48% for 
microspheres exposed to 75% relative humidity for 24 hours prior to incubation.
Microencapsulation of a conformationally labile protein was proven successful. 
Also, the work highlighted that certain non-ionic surfactants should be considered 
further as prospective stabilisers for the w/o/w emulsion-evaporation technique.
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The number of protein, peptide and more recently DNA based drugs has been 
increasing over the past decades. Along with it, the need to develop safe routes of 
administration has become clearer. However, it is difficult to use these compounds in 
the context of oral or intravenous administration because of their structural fragility, 
low bioavailability and short half-life (Johnson & Tracy 1999; Lee 1995). Maintaining 
constant drug concentrations in vivo for an extended period of time is problematic and 
often resolved via frequent injections of high doses. In the case of patients with type I 
diabetes, daily injections are required, generally from 1 to 4 times a day. The health 
care professional reviews blood glucose levels to determine the appropriate type of 
insulin the person should use. More than one type of insulin may be mixed together in 
an injection to achieve the best control of blood glucose. Ideally, oral administration 
would be preferred as it is more acceptable to the patients, it does not require trained 
personnel, and oral drugs are generally cheaper to manufacture.
In order to avoid the problematic instability of therapeutic compounds, the use 
of biodegradable and non-biodegradable polymers has been extensively studied. 
Originally, the objective was to design a controlled-release delivery system for
2proteins and peptides (Mathiowitz et a l 1997). The resulting product has to conform to 
the pharmaceutical regulations whereby it must be non-immunogenic, easily 
reproducible, stable to store, and appropriate for large-scale manufacturing. Suitable 
polymeric candidates include polyesters well known for their biodegradability and 
biocompatibility. These include poly lactic acid (PLA), poly glycolic acid (PGA) and 
especially poly(lactic-co-glycolic acid) (PLGA). PLGA is the main polymer used 
because it is approved by the Food and Drug Administration (FDA) (Jain 2000). Its 
low immunogenicity and toxicity, its good mechanical properties and predictable 
biodegradation kinetics enable its use from microspheres to bone tissue engineering, 
and other medical applications (Beumer et a l 1994).
Among the controlled-release delivery systems studied, one interesting 
approach has been the encapsulation of bioactive compounds into biodegradable 
particles of a micron- or nano-scale. The micro- or nanospheres would release the drug 
entrapped either in a continuous or pulsatile manner according to the therapeutic 
prerequisites (Cleland 1997). There exist several protocols to manufacture 
microparticles, yet many of them are only a derivative of the most basic encapsulation 
method, known as water-in-oil-in-water (w/o/w) double emulsion solvent-evaporation 
method (Cleland 1997). Although this technique is the most preferred for the 
encapsulation of hydrophilic proteins, it is not without problems. During microsphere 
fabrication via the w/o/w system, the primary emulsion (water-in-oil) has been proven 
to be the most destructive step with respect to protein stability (Blanco & Alonso 
1998). On account of this, improved displacement of the protein from the interface by 
a surfactant would facilitate preservation of the protein's native conformation (van de 
Weert et a l 2000a).
In this study, seven emulsifiers were chosen to enhance the stability of an 
integrin-binding protein FIII9'-10, the 9th and 10th Fibronectin type HI domain pair, 
encapsulated into PLGA microspheres. The five non-ionic surfactants listed hereafter 
were selected due to their compatibility with protein structure and emulsion stability: 
Pluronic F68, Tween 20, Tween 80, Triton X-100 and Igepal CA-630. In addition, 
bovine serum albumin (BSA) and polyvinyl alcohol (PVA) were used as model 
reference. Seven different types of microspheres were subsequently produced. Each 
type of microsphere was first characterised with respect to protein encapsulation 
efficiency, protein release, protein integrity and protein biological activity. This work 
was accompanied by a more physico-mechanical oriented study of the polymer with
3the aim to dissect and comprehend the underlying molecular interactions between 
surfactant and drug/PLGA.
These analyses necessitated a thorough understanding of three main points: 
microsphere engineering, PLGA properties, and protein characteristics. This chapter 
outlines some of this knowledge, preceded by an overview of pharmaceutical 
application of biodegradable microparticles. The morphological features and the 
biodegradation profiles of microspheres are then described, and some essential 
definitions related to the polymer are presented, with special emphasis on its 
mechanical stability. Finally, some background information is given on the integrin- 
binding protein FIII9'-10.
1.2 Pharmaceutical application of PLGA 
microspheres
The use of biodegradable microspheres for drug delivery is not limited to any 
specific illness or administration route. An impressive list of encapsulated therapeutic 
agents already exists and illustrates the great potential of biodegradable microparticles 
for medical purposes. Antibiotics (Atkins et al. 1998), peptides (Li et al. 1995), 
proteins (Yan et al. 1994), DNA (Mohamed & van der Walle 2006), antibodies 
(Homayoun et al. 2003), anaesthetics (Le Corre et al. 1997), anti-virals (Schlicher et 
al. 1997), anti-hypertension drugs (Sansdrap et al. 1999; Yuksel et al. 1996), anti-HIV 
drugs (Akhtar & Lewis 1997), anti-cancer drugs (Lin et a l 2005) etc, have been 
encapsulated and tested as potential commercial products. Studies also extended 
further with industrial applications orientated towards marine fish culture or veterinary 
products (Matschke et al. 2002; Yang et al. 2001). Table 1.1 compiles a selection of 
drug microencapsulated and examined as candidates for drug delivery.
4Drug Format Report Reference
Bromodeoxyuridine PLGA
microspheres
in vivo cell labeling
efficient labeling at cortical lesion site
May singer et al., 1994
5-Fluorouracil PLGA
microspheres
in vitro release 
release for up to 21 days
Boisdron-Celle et al., 




increase in animal survival correlated 
with release rate
Menei et al., 1996 and 
Roullin et al., 2003
Iododeoxyuridine PLGA
microspheres
in vitro release 
release over 7-35 days






reduction in rotational behavior for up to
8 weeks
McRae and Dahlstrom, 




in vitro release; in vivo treatment of 
vitreoretinopathy model 
release for up to 40 days; reduction in 




in vitro release 
release over 60 days
Feng et al., 2000
Paclitaxel PEG-PLA
microspheres
in vivo intravenous release
higher drug tissue levels than seen with
direct injection
Kim et al., 2001
Carboplatin PLGA
microspheres
in vitro release 
release over 22 days
Chen and Lu, 1999
Carboplatin PLGA
microspheres
in vivo intracerebral release 




in vitro release; in vivo subcutaneous 
release
released over 49 days; detectable in 
plasma for 49 days
Dutt and Khuller, 2001
Estradiol PLGA
microspheres
in vitro release 
release over 40-60 days
Bimbaum et al., 2000
Hormone agonist PLGA implant in vivo subcutaneous release 
release over 20-50 days
Heinrich etal., 1991
Table 1.1. List of bioactive compounds encapsulated in PLGA micro spheres and 
studied as potential drug delivery system for medical application (Whittlesey & Shea 
2004).
For microparticles fabrication at an industrial scale, equipment needs to be 
replaced and adapted for controllable, economic and aseptic conditions. An interesting 
review written by Freitas et al. examines some of the technologies available for 
microsphere preparation, with a particular attention dedicated to droplet formation
5(Freitas et al. 2005). It is suggested that evolution of the water-in-oil droplets, embryos 
of the future microspheres, is one of the most critical steps and therefore, extreme 
caution must be taken at this stage. A variety of apparatus and protocols, such as static- 
mixing, extrusion through membranes, microfabricated microchannel devices, needles, 
or dripping using electrostatic forces and ultrasonic jet excitation, are described and 
reviewed as some may have potential in the industrial environment. Peptide and 
protein microencapsulation continues to represent a technological challenge in terms of 
product sterility and scale-up. Nevertheless, some biodegradable drug delivery systems 
summarised in Table 1.2 are already commercially available.
Applicant Name of Product Active Ingredient Dosage Form
TAP Pharmaceutical Products Inc. Lupron® Depot Leuprolide Microspheres
TAP Pharmaceutical Products Inc. Enantone® Depot Leuprolide Microspheres
Genentech Inc. Nutropin® Depot Somatropin Microspheres
Pharmacia & Upjohn Company Trelstar® Depot Triptorelin pamoate Microspheres
Ipsen and Ferring Pharmaceuticals Company Decapeptyl® Triptorelin pamoate Microspheres
Novartis Pharmaceuticals Corp. Sandostatin LAR® Depot Octreotide Microspheres
Novartis Pharmaceuticals Corp. Parlodel® Depot Bromocriptine mesylate Microspheres
Astra Zeneca Pharmaceuticals LP. Zoladex® Goserelin actetate Rod implant
Atrix Laboratories Inc. Atridox® Doxycycline Gel
Table 1.2. Selection of commercially available drug delivery systems, all using PLGA 
as a biodegradable carrier.
While the list of candidates for microencapsulation is rather long, the number 
of bioactive compounds passing all trials in a successful manner is rather small. In 
effect, studies investigating the encapsulation of model proteins, such as bovine serum 
albumin (BSA) and lysozyme, have demonstrated the ability to recover the protein 
intact upon release in vitro and in vivo. However, the encapsulation of a variety of 
proteins, peptides or vaccines exhibited different results than those of the model 
proteins presumably because of their structural stability, and high amphipathicity in the 
case of BSA. This suggests that protein encapsulation is specific to each new protein 
loaded, necessitating individual tests and trials (Okumu et al. 1997; Sah 1999b).
6Further research is necessary in order to better understand and control the mechanisms 
underlying protein instability, encapsulation efficiency, in vitro and in vivo release 
profiles, and degradation. Successful findings in this line of research would extend the 
use of biodegradable microspheres to a wider range of drugs, applications, and 
administration routes.
1.3 Microencapsulation techniques
The success of a microencapsulation technique depends primarily on the 
physicochemical properties of the polymer and the drug. The right method must be 
selected to ensure the satisfaction of three main criteria:
♦ The biological activity of the drug must not be altered in order to avoid an 
immune response.
♦ The size of the particles has to support the administration route aimed (from 
nanoparticles for injectable particles, to microns for oral administration or 
pulmonary delivery).
♦ The drug release profile must be appropriate to the intended medical 
application (long term release, pulsatile or delayed release).
Although a number of encapsulation processes have been developed, they all 
share a similar first step where the drug is dispersed in an organic polymer solution 
and emulsified. Typical microencapsulation techniques are reviewed below.
1.3.1 Solvent evaporation process
Solvent evaporation is the most frequently used encapsulation technique due to 
its ease of manipulation, low cost, and rapid completion of microsphere fabrication 
(Cohen et al. 1991; Jeffery et a l 1993). The advantage most appreciated remains its 
suitability for either hydrophobic or hydrophilic drugs by following a single oil-in- 
water (o/w) emulsion or a double water-in-oil-in-water (w/o/w) emulsion, respectively. 
In each case, the precipitating polymer confines and encapsulates the drug into the 
hardening particles during the extraction step.
7The single oil-in-water (o/w) emulsification is commonly preferred in the case 
of lipid-soluble drugs for the reason that the compound is directly added to the oil 
phase (Jeffery et a l 1991). The oil is prepared with polymer and drug dissolved in 
organic solvent, generally dichloromethane (DCM). The drug is evenly dispersed 
within the oil phase, and the suspension is emulsified in a large amount of water 
containing a stabiliser, usually PVA. The emulsion is then left to stir over a sufficient 
period of time during which solvent is removed by extraction into the continuous 
aqueous phase and evaporation at the air-liquid interface. The lifetime of the emulsion 
is generally no more than seconds to minutes, and during this time the polymer 
precipitates at the solvent front, leading the shell to harden progressively toward the 
centre of the sphere, and shrinking until the final size of the microspheres is stabilised 
(Jeyanthi et a l 1996; Yang et a l 2000). The particles are then collected by filtration or 
centrifugation, washed, and dried overnight, usually by lyophilisation.
In comparison with the single emulsion, the water-in-oil-in-water (w/o/w) 
double emulsion is more suitable for water-soluble drugs (Cohen et a l 1991). The 
process is divided in two successive emulsions which are illustrated in Fig. 1.1. The 
primary water-in-oil emulsion is prepared with an inner aqueous phase, containing the 
hydrophilic drug occasionally combined with a surfactant, and a continuous oil phase, 
this being the polymer dissolved in solvent. The two immiscible phases are sonicated 
or homogenised yielding small aqueous droplets dispersed in oil. The first emulsion is 
then transferred into a larger volume of water containing a stabiliser, generally PVA, 
and stirred. The extraction and evaporation of the solvent inducing the solidification of 
the particles is maintained until completion of solvent removal. Finally, the 
microspheres are centrifuged, washed, and dried.
Single and double emulsification, do not require elevated or low temperatures 
unless particular conditions are necessary (Yang et a l 2000). Particles can be 
manufactured at a nano- or micrometer size by regulating the stirring speed of the final 
emulsion or rate of DCM extraction (De & Robinson 2004). Most importantly, the 
drug is usually homogeneously distributed throughout the matrix of the microparticles 
(Yang et a l 2001). However, drug loss may be considerable during solvent removal, 
and more particularly in the case of the double emulsion due to the inevitable exchange 
flow between the inner and outer water phases (Yang et a l 2001). The presence of the 
inner water droplets in the first emulsion of the water-in-oil-in-water formulation 
makes coalescence hard to avoid unless surfactants or stabilisers are initially
8incorporated to the inner water phase (Capan et al. 1999). These difficulties can be 
significantly reduced in the case o f lypophilic drugs since the unnecessary first water 
phase is withdrawn from the formulation steps. The encapsulation procedures then 
becomes a solid-in-oil-in-water (s/o/w) where the solid protein is directly dispersed 
into the oil phase, emulsified and then transferred to the continuous water phase for 
solvent extraction (Castellanos & Griebenow 2003).
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Figure 1.1. Schematic representation o f  the two process steps in microsphere 
preparation by double emulsion solvent evaporation technique.
91.3.2 Phase Inversion Nanoencapsulation 
technique or Coacervation
Coacervation, also called Phase Inversion Nanoencapsulation (PIN), consists of 
a phase separation process leading to the formation of micro- or nanospheres (Nihant 
et al 1993). The first stage follows a standard water-in-oil emulsion where the water- 
soluble or solid drug dispersed in an aqueous phase is stirred into an oil phase 
composed of the polymer dissolved in DCM. An organic non-solvent, or coacervating 
agent such as poly(dimethylsiloxane), is then added to the first emulsion and stirred to 
create a water-in-oil-in-oil emulsion. Although a non-solvent does not permit the 
solubility of either polymer or drug, it allows for the diffusion of the polymer solvent 
which brings the polymer to form very soft coacervate droplets entrapping the drug. 
The physically stabilised coacervate droplets are then transferred to a hardening agent, 
in fact a second volatile non-solvent such as hexane, heptane or petroleum. This 
ultimately removes the coacervating agent causing the microspheres to fully harden. 
Finally, the microspheres are collected, washed and dried.
In this technique, drug loss may occur during phase separation and the 
formation of coacervate droplets (Nihant et al 1994b). In effect, the polymer must be 
given enough time to deposit and homogeneously coat the drug particles (Ruiz et al 
1990). This depends on the polymer solvent extraction rate, which is regulated by the 
addition rate of the first non-solvent. Another problem to consider is the sticky 
consistency of the beads that tends to create agglomerates of coacervate droplets 
(Thomasin et a l 1998). This can be rectified by modifying the stirring rate, 
temperature, or by incorporating additives. By adjusting process factors such as 
solvent extraction, addition rate and temperature, a satisfactory result can be achieved 
and the microparticles can be made to conform to the traditional criteria of micron or 
nanoscale, uniform drug dispersion, etc. However, residual amounts of DCM and 
hardening agents are often found in the microspheres (Thomasin et a l 1996). Attempts 
to minimise the presence of potentially harmful residues are being undertaken by 
investigating the use of supercritical gases instead of non-solvents.
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1.3.3 Spray drying method
Spray drying is a very rapid and convenient method, although it requires a fine 
control of the temperature (Walter et al. 2001). Briefly, the drug is mixed with the 
polymer dissolved in solvent and spray dried through a small nozzle onto liquid 
nitrogen with an underlying layer of frozen extraction solvent, generally ethanol. By 
decreasing the temperature to -80°C, the liquid nitrogen disperses and the 
microparticles are suspended into the cold liquid ethanol allowing the extraction of the 
polymer solvent. The microspheres are washed again in cold liquid ethanol and 
collected by filtration which allows for residual solvents to evaporate. Finally, they are 
dried by lyophilisation.
Spray drying is relatively straight forward but is unfortunately inappropriate for 
the bioactive compounds which are highly delicate and sensitive to temperature (Fu et 
al 2001). The technique also requires fine control of inlet and outlet air-temperature 
and air flow. The latter may cause significant loss of the product due to the adhesion of 
the soft particles to the inner wall of the spray drier machinery (Chew & Chan 1999). 
To date, compounds of a variety of sizes and types, such as tetanus and diphteria 
toxoids (Peyre et al. 2003), tetracosactide (Witschi & Doelker 1998), somatostatine 
analogue (Blanco-Prieto et al. 1999) and anticancer drugs (Fu et al. 2001; Gavini et al. 
2004; Lin et al. 2005) have been successfully encapsulated via spray-drying, but 
relatively little information on the effects of the formulation variables is available 
(Gavini et al. 2004).
1.3.4 Precipitation using gases in the supercritical 
state
Approximately ten years ago, three main processes based on supercritical 
precipitation emerged. The outline of these techniques remains invariable: the drug is 
added to an organic phase containing PLGA, and the solvent is then extracted to allow 
microsphere hardening. All three formula utilize compressed supercritical carbon 
dioxide (CO2) fluid to precipitate the organic solution (Eckert et al. 1996). However,
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each technique is characterised by a particular precipitation mode listed below and 
illustrated in Fig 1.2:
♦ precipitation with gaseous anti-solvent (GAS),
♦ precipitation with a compressed anti-solvent (PCA),
♦ precipitation by rapid expansion from supercritical solution (RESS).
In the GAS process, the drug-polymeric solution is emulsified and exposed to 
carbon dioxide in the gaseous, liquid or supercritical state. As carbon dioxide dissolves 
into the organic solvent, the polymer precipitates into microspheres (Randolph et al 
1993).
The process of precipitation with a compressed anti-solvent (PCA) is a semi- 
continuous mode of fabrication. The organic solution containing the active ingredient 
is atomized into a continuous flow of supercritical CO2 . As the organic solvent diffuses 
into the excess CO2 , the atomized droplets harden and the solid microspheres fall in 
the particle collector. This technique offers the advantage to form microparticles faster, 
of a smaller particle size, and in a semi-continuous manner. Other processes based on 
the same principle have been given different names, such as: aerosol solvent extraction 
system (ASES), supercritical anti-solvent (SA), and solution-enhanced dispersion by 
supercritical fluids (SEDS) (Bleich et a l 1993; Witschi & Doelker 1998).
Finally, in the RESS process, the drug-polymer solution is dissolved in 
supercritical fluid as anti-solvent and the pressure of the suspension is elevated. The 
high-pressure solution is atomized through a nozzle into a collection chamber at 
ambient condition and pressure. Effectively, the process is based on the solubility 
differences of the polymer in supercritical fluids at high and low pressures, 
respectively. At ambient pressure, the CO2 of the fine particles of solute expands 
rapidly while extracting the organic solvent. Fast polymeric precipitation follows and 

















Figure 1.2. Schematic representation o f the three main techniques o f precipitation 
using supercritical carbon dioxide: (A) precipitation with gaseous anti-solvent (GAS), 
(B) precipitation with a compressed anti-solvent (PCA), and (C) precipitation by rapid 
expansion from supercritical solution (RESS) (Subramaniam et al. 1997).
1.4 Variations of the fabrication techniques
1.4.1 Double-walled microspheres
Double-walled microspheres were developed to circumvent the problem of the 
initial burst release and also for improved control of drug release profiles (Pekarek et 
al. 1994). Specifically, an external shell acting as rate-limiting barrier is added to the 
loaded microparticles. Several techniques result in this two-layered structure, one of
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them being to simply coat conventional microparticles with a second polymer (Tsung 
& Burgess 2001). Another method relies on the mechanism of phase-separation of two 
polymers brought to their critical concentrations, most commonly poly(L-lactic acid) 
(PLLA) and poly(D,L-lactic-co-glycolic acid) (Mathiowitz & Langer 1989). Under 
such circumstances, the two polymers combined in organic solvent are immiscible 
(Dobry & Boyer-Kawenoki 1947). Briefly, the polymers are first dissolved in solvent 
and mixed before transfer to a continuous aqueous phase. As the solvent progressively 
evaporates, the concentration of the polymer-polymer droplets increases and 
ultimately, the polymers phase-separate. The resulting distinct structure of double­
walled PLLA/PLGA microspheres is arranged with PLLA as the shell, and PLGA as 
the core.
Double-walled microspheres demonstrate the advantage of slow release and 
slow degradation rates which are necessary for extended therapeutic delivery (Lee et 
al. 2002). However, in order to avoid the formation of an external shell which would 
not control the drug release but only delay the initial burst, extended work is necessary 
to determine the correct conditions of fabrication of double-walled microspheres. Also, 
it is important to keep in mind that these encapsulation techniques are not appropriate 
for small sized microspheres (Liu et al. 2004).
1.4.2 Use of grafted-polymer
There have been many attempts to modify the chemical composition of PLGA 
in order to render it more compatible with specific applications. The chain length and 
the PLA/PGA ratio are commonly the first variations suggested. A broad range of 
molecular weight and PLA/PGA fractions are now commercially available. Also, a 
more hydrophilic (-COOH) uncapped variety of PLGA can be purchased and used for 
a faster degradation rate, whereas end-capped PLGA generally resists for longer 
(Friess & Schlapp 2002).
More complicated chemical adjustments have been used to prolong the 
circulation time of nanoparticles via PEGylation, a conventional method conjugating 
polyethylene glycol (PEG) to PLGA or PLA (Jeong et a l 2000). In addition, 
PEGylation reduces the detrimental effect of protein adsorption onto the particles 
(Jeong et al. 2000). In a different study led by Pistel et al., PLGA chains were enriched
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with additional polymers grafted onto their backbone by melt polymerisation (Pistel et 
al 2001). Polyvinyl alcohol-grafted-poly(lactic-co-glycolic acid) decreased drug 
release when long PVA chains were inserted. Oh et a l followed a new approach, and 
obtained a drug release determined by mass erosion of PLGA matrices after 
conjugating the drug directly to the PLGA chain via ester linkage (Oh et al. 1999). The 
variety of coupling reactions extends further and is in fact limited solely by the 
therapeutic application of the polymer.
1.4.3 Biodegradable implant formed in situ
The biodegradable nature of PLGA has received considerable attention from 
groups investigating implants which could be injected into the body via a syringe, and 
would simply be eliminated after progressive biodegradation (Hatefi & Amsden 2002). 
These polymeric implant systems are formulated to solidify in situ upon intramuscular 
or subcutaneous injection (Lambert & Peck 1995). Briefly, the polymer is dissolved in 
a biocompatible solvent such as dimethyl sulfoxide (DMSO) or N-methyl-2- 
pyrolidone (NMP), and mixed with the drug to produce a solution of low viscosity to 
allow injection through a needle. After injection, the biocompatible solvent is extracted 
from the solution while the local aqueous environment causes the insoluble polymer to 
form a gel matrix. As the polymer hardens, the drug begins to diffuse out and is slowly 
released until complete degradation of the implant.
A variety of active compounds such as LHRH antagonists (Radomsky et al 
1993; Rawarapu et al 2000) and narcotic antagonists (Dunn et al 1996) have already 
been injected and tested. The ease of application, the ability to localise delivery for a 
site-specific action and improved patient compliance and comfort support the success 
of this formulation. However, an initial burst release during the first hours after 
injection has been repeatedly noticed. The lag between injection and formation of the 
implant has been verified to be the origin of the burst release (Shively et a l 1995).
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1.5 Characteristics of microspheres
1.5.1 Morphology of microspheres
During microsphere fabrication, slight changes in the formulation parameters 
can have radical effects on microsphere morphology (Yang et al. 2001). 
Reproducibility is hard to obtain when working at small scale (milligram), and in order 
to understand and control the impact of manufacturing processes, a detailed insight in 
the external and internal morphology is necessary. Physical characterisation aids in 
comprehending the stresses applied during the preparation of the particles, and 
determines future medical application (Florence 1997).
External morphology can be defined as microsphere size and shape, external 
porosity and surface roughness. The inner porosity and pore network determine the 
internal morphology. Most of the techniques used for the analysis of the microspheres’ 
structure have the advantage of being reliable and easily reproducible (Table 1.3). 
Therefore, morphology has been more intensively studied than other features of the 
microspheres, and detailed descriptions are provided in the literature.
External Morphology Internal Morphology
Feature Method Feature Method
Overall Shape Scanning Electron 
Microscope (SEM)
Overall Shape SEM and Cryo-SEM
Size Transmission Electron 
Microscope (TEM)
Pore Size TEM
Topography Atomic Force Microscope 
(AFM)
Drug distribution LS Confocal Microscope
Size o f the spheres Light scattering 
techniques
Pores radius <10  
pm
Mercury porosimetry
External porosity Dye encapsulation Pores radius in the 
range o f 10-75 
pm
Dilatometry
Table 1.3. Commonly used methods to visualize the external and internal features of 
the microspheres.
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1.5.1.1 External morphology of microspheres 
Size of the microspheres
Clearly, size is a key factor that affects not only the drug loading and the initial 
burst release, but also the utility of the particles (Deng et a l 1999; Florence 1997; 
Prabha et a l 2002). In a w/o/w emulsion, both the first and second emulsions offer the 
opportunity to fine-tune the microsphere size. In the primary emulsion, increasing the 
volume of the aqueous phase leads to larger particles (Jeffery et al 1993). Similarly, 
certain variations of the oil-phase composition may lead to a more viscous state less 
easily breakable, thus producing larger spheres. The best known modifications 
increasing the oil-phase viscosity consist in using a high polymer concentration, a high 
PLGA molecular weight, or adding gelatine to the oil (Jeffery et a l 1993; Mehta et a l 
1996; Witschi & Doelker 1998; Yang et a l 2001). Microparticles are also reported to 
enlarge slightly when the drug/PLGA ratio increases (Park et a l 1995). The addition 
of non-ionic surfactants within the inner aqueous phase has only a small effect on 
microsphere size (Rojas et a l 1999).
The secondary emulsion also influences microsphere size. Addition of PVA to 
the external aqueous phase impedes the coalescence of the spheres, and their size 
reduces significantly as the PVA concentration is increased (Jeffery et a l 1993). Also, 
high stirring speeds improve the breakdown of the first emulsion (Yang et a l 2001). 
Increasing the volume of the continuous aqueous phase leads to larger particles due to 
rapid solvent extraction (Crotts & Park 1995; Jeffery et al 1993). Temperature also 
affects particle size: at high temperatures (40°C), solvent evaporation is significantly 
faster such that the PLGA precipitates nearly instantaneously without shrinking, 
leading to large particles (Yang et al 2000).
External porosity of the microspheres
The formation of external pores originates from the flow between the inner and 
outer water phases driven by osmotic pressure. Consequently, porous surfaces are
17
generally observed when a high volume fraction of aqueous phase is used in the 
primary emulsion (Crotts & Park 1995; Okumu et al 1997). It was also found that the 
pore sizes and numbers are higher as the concentration of drug increases (Witschi & 
Doelker 1998). This could be related to the displacement of the drug from the inner to 
the continuous water phase which would generate a pore proportional to the drug’s size 
(Sandor et al. 2001). When non-ionic surfactant is added to the inner water, the 
porosity is markedly affected, but the prediction of the resulting porosity is harder 
(Bouissou et al. 2004). The external porosity is an important parameter as it has been 
reported to regulate the drug release rate as well as the water inflow and outflow 
during in vitro release (Wang et al. 2002). It is less clear whether drug entrapment is 
improved when a nonporous particle is specifically fabricated (Cleland et al. 1997; 
Mehta ef a l 1996).
Surface roughness
Recently, biodegradable microspheres as drug carriers have been applied to 
pulmonary delivery (Bivas-Benita et al. 2004; Suarez et al. 2001). It has been shown 
that increased surface roughness of particles demonstrate a lower powder cohesiveness 
(Chew & Chan 2001), and that the surface morphology and roughness of microspheres 
can be directly modified with the addition of non-ionic surfactants (Bouissou et al 
2004). On the other hand, a smooth surface with micropores is easily obtained with 
PLGA 75/25 (Cohen et a l 1991).
1.5.1.2 Internal morphology of microspheres
The internal morphology corresponds to the spherical ‘cavities’ or ‘pores’ 
dispersed throughout the polymeric matrix, and the network of channels linking these 
pores. Although the cavities materialise during the secondary emulsion while the 
solvent evaporates, they are thought to originate from the inner water droplets formed 
during the first emulsion (Schugens et al 1994). Considering that the water droplets 
also carry the drug, a homogeneous spread is preferred in order to moderate the
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phenomenon of initial burst release often reported (Yang et al 2000). An even porosity 
also improves the draining of the acidic PLGA degradation products which contributes 
to maintain the internal pH closer to the physiological pH (Kim & Park 2004a). 
However, there is no clear correlation between the number and size of cavities and the 
liberation of the polymeric fragments (Crotts et al. 1997).
Throughout the w/o/w method, there exist several processes which can 
substantially influence the internal morphology of the microspheres. During the 
primary emulsion, the use of a high shearing rate can break the water droplets down to 
small sizes (Rafati et al 1997). Low viscosity of the oil-phase also facilitates the 
breakdown of the inner water phase. Consequently, a low volume of oil-phase is often 
chosen (Yang et al 2001). It is reported that smaller proteins are more homogeneously 
distributed within the sphere, and the porosity is more consistent than for large proteins 
of approximately 200 kDa (Sandor et a l 2001). The secondary emulsification may also 
affect the internal porosity (Schugens et a l 1994). At low temperatures, the 
evaporation of the solvent progresses slowly and eventually, the inner water droplets 
might merge if their stability is too poor (Yang et a l 2000). Coalescence also takes 
place more frequently when the polymeric molecular weight is low (Witschi & 
Doelker 1998).
1.5.2 Biodegradation of microspheres
1.5.2.1 Description of the biodegradation process
Drug release and biodegradation of microspheres are interdependent (Cleland 
et al 1997; Lemaire et a l 2003). The process of biodegradation of microspheres 
consists of a random hydrolysis of the ester linkages of the PLGA chain (Gopferich & 
Langer 1995). There exist two possibilities with respect to the degradation of the 
polymer that are dependent on the sphere’s dimension and the pH of the incubation 
medium. According to circumstances, the degradation can either be faster than the 
water uptake, which then dilapidates only the surface (surface erosion), or the water 
can rapidly penetrate the whole structure before surface erosion begins (bulk erosion) 
(Burkersroda et a l 2002).
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In the case of surface erosion, the slow progress of water results in a 
heterogeneous dispersion through the matrix, as illustrated in Fig. 1.3. Meanwhile, the 
erosion operates at a constant velocity leading to a reduction in microsphere diameter. 
In bulk erosion, water is homogeneously distributed within the matrix such that 
hydrolysis occurs throughout (Batycky et al. 1997). The sphere tends to maintain its 
original size for longer while eroding from within (Deng & Uhrich 2002). It has been 
determined that in the case of PLGA, extremely large spheres would undergo surface 
erosion whereas small spheres would bulk-erode (Burkersroda et al. 2002).
In drug delivery applications, the requirement for micron sized particles 
necessitates a better understanding of the bulk erosion mechanism (Desai et al. 1997; 
Prabha et al. 2002; Zauner et al. 2001). Considering the rapid and extended access of 
water throughout the particles, it was originally assumed that an immediate loss of 
mass would be displayed as soon as the chain hydrolysis was triggered. Unexpectedly, 
a study conducted by Burkersroda et al. demonstrated that the mass loss appears 
somehow delayed despite an instantaneous loss in molecular weight, as seen in Fig. 1.4 
(Burkersroda et al. 2002). Consequently, the mass loss is not only regulated by the 
chain scission, but also by a side effect that obstructs the polymeric pieces from 
leaving the microsphere, thus postponing its starting point. To describe this mechanism 
more precisely, the following two concepts were introduced: “degradation” which is 
the microsphere loss in mass, and “erosion” which is the microsphere loss in molecular 




Figure 1.3. Schematic representation o f the two modes o f microsphere biodegradation. 
Surface erosion leads to a reduction in the microsphere diameter, whereas bulk 
erosion deteriorates homogeneously the matrix o f the microsphere, even in the centre.
In order to explain the delay in mass loss, the following assumption was 
proposed. As water infiltrates the sphere, random hydrolysis occurs throughout the 
structure, segmenting the polymeric chain into various sizes and solubilities. 
Dissolution of the acidic polymeric segments leads to the expansion of the inner 
cavities. Due to the accumulation of acidic products in the water, the pH decreases, 
enhancing the hydrolysation even more. By this stage, the molecular weight of the 
microsphere has reduced, whereas the mass still remains relatively unchanged. 
Eventually, diffusion is facilitated by the enlarged cavities and interconnecting 
channels, driving the chain fragments to the release medium. Only then does the sphere 
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Figure 1.4. Illustration o f molecular weight loss (MWt/MWto) and mass loss (mt/mto) 
profiles o f microspheres undergoing either surface erosion or bulk erosion. The loss is 
expressed as the ratio o f the initial load. Note the delay in mass loss during bulk 
erosion (Burkersroda et al. 2002; Husmann et al. 2002).
One has to bear in mind that the in vitro models may not entirely reflect the 
complexity of the in vivo environment (Blanco-Prieto et al. 1999; Johansen et al. 2000; 
Park et al. 1995). Traditional protocols of in vitro incubation prescribe pre-defined 
volumes of release medium of phosphate buffer saline (PBS) at pH 7.4 containing a 
preservative, such as sodium azide, and occasionally a surfactant. In this context, the 
pH tends to lower faster because of enhanced autocatalysis (Park et al. 1995). Even if 
the buffer is replenished frequently, the enclosed conditions do not allow the rapid 
removal of the acidic products released by the degradation. In this case, the pH values 
vary according to the size of the spheres (Fu et al. 2000), therefore mass and molecular 
weight loss data have to be analysed bearing in mind the inaccuracy of the method 
employed. Similarly, in vitro protein release data, which are generally produced by the 
same method of incubation, do not entirely reflect the situation in vivo. Unfortunately,
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the complexity of the parameters involved makes it difficult to find an appropriate 
protocol, although attempts have been made to predict and even control the 
mechanism.
1.5.2.2 Control and prediction of the degradation profile
The following list summarises the factors that determine the degradation of the 
polymer:
♦ the type of polymer
♦ the type of drug
♦ the morphology of the matrix
♦ the diffusion of water
♦ the polymer degradation products
♦ the pH
♦ the osmotic pressure
Two different approaches aiming to control degradation have been employed; 
namely the modification of the chemical structure of the polymer and the alteration of 
its mechanical properties. The first approach is based on the regulation of the process 
of hydrolysis. There are several factors that influence this process:
♦ the relative stability of the polymer backbone, i.e. the bond half-life at 
physiological pH and temperature.
♦ hydrophobicity, which is principally governed by the number of glycolic acid 
units present in the PLGA chain.
♦ steric effects, as the alkyl group of the lactic acid units hinders the water access 
to the ester bonds (Gopferich 1996).
♦ autocatalysis, as the accumulation of acidic products lowers the pH, thus re­
enforcing the attack on the ester linkage.
To control chain hydrolysis, the type of PLGA must be chosen in accordance 
with the degradation profile desired. For instance, varying the proportion of PLA/PGA 
or the chain length leads to different degradation speeds (Cleland et a l 1997;
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Gopferich 1996; Park 1995; Witschi & Doelker 1998). Ester bonds linked with the 
glycolic acid units (i.e. Glyc/Glyc or Glyc/Lact) have a high hydrolytic reactivity (Park 
1995; Shih et al. 1996). Therefore, a PLGA with a ratio 75/25 exhibits a longer 
degradation than a PLGA 50/50 due to a higher number of lactic acid units (Park
1995). For PLGA 50/50 of different molecular weights, the monomer arrangement 
within the chain dictates the degradation rate (Witschi & Doelker 1998). Similarly, 
scission at the chain-end is faster than degradation of the internal bonds (Shih et al
1996). Consequently, the direct alteration of the chain backbone has been explored in 
order to achieve better degradation profiles. In contrast to free COOH-terminal 
polymer, end-capped polymer with lactic-acid-ethyl-ester delays bulk erosion 
(Burkersroda et al. 2002; Mehta et a l 1996). Similarly, the direct conjugation of the 
polymeric backbone to the drug has been analysed: the drug-PLGA conjugate is 
processed into microspheres and its extraction is controlled by the polymer degradation 
(Oh et al. 1999; Yoo et al. 2000; Yoo et al. 1999). Conjugation of the polymeric 
backbone with PVA also yields different degradation characteristics (Pistel et al.
2001). PVA-grafted PLGA induces a lower burst release and a more continuous 
release profiles.
The second approach aiming to control the biodegradation process is based on 
the alteration of the mechanical properties of the polymeric chains. The property of 
most relevance is the mobility of the PLGA chain, which is determined by the glass 
transition temperature (Tg) (Nam & Park 1999). During incubation, the molecular 
mobility of the polymeric structure eases the infiltration of the water molecules, which 
in return initiates hydrolysis more rapidly. Elimination of degradation products and 
shorter PLGA chain length create free volumes. The additional spaces permit even 
greater hydrolysis, and lead to faster degradation (Ali et al. 1993). Therefore, any 
factor rendering the polymer more plastic is likely to enhance the degradation rate; 
examples would include plasticizers such as non-ionic surfactants added during 
fabrication. Alternatively, amorphous PLGA made of more than 30% of PLA 
undergoes faster degradation than crystalline PLGA comprising less than 30% PLA 
(crystalline materials retain degradation products mostly due to stiffness) (Ford & 
Timmins 1989; Park 1995). Also, storage conditions impact on the material 
characteristics of microspheres (Aso et al. 1994; Deng & Uhrich 2002).
Several mathematical models for the prediction of the degradation profile have 
been proposed (Batycky et al. 1991; Gopferich 1997; Gopferich & Langer 1995;
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Siepmann & Gopferich 2001; Zhang et al. 2003). Ideally, given certain factors such as 
the size of the sphere, the molecular weight of the polymer and its lifetime, it should be 
possible to simulate the erosion, and by tuning these parameters to achieve the desired 
profile. Unfortunately, the difficulty of obtaining reliable mathematical models arises 
from the multitude of parameters that must be taken into account. So far, no single 
mathematical model has succeeded in conforming closely to the observed data.
1.5.3 Drug release
The release of any drug from a polymeric device involves the diffusion of the 
therapeutic compound out of the structure via osmotic pressure (Yang et al 2001). 
Generally, a fast liberation of drug located nearby the particle surface generates an 
initial burst release, often thought as problematic. A recent study conducted by 
Messaritaki et al. suggested that the swelling properties were also responsible for the 
burst release phenomenon (Messaritaki et al. 2005). Techniques have been developed 
to decrease the initial burst through the addition of an external polymeric layer (Lee et 
al. 2002).
The diffusion profile following the burst release is dependent on polymeric 
transformations occurring prior to and throughout incubation. Such changes include 
physical plasticization attributed to the effect of moisture during storage, as well as the 
direct contact with water during incubation. In both cases, the drug release is 
drastically accelerated in conjunction with the degradation rate (Friess & Schlapp
2002). It was also suggested by Steedam et al. that the transition from the glassy state 
to rubbery state during incubation may alter the drug release profile by changing the 
internal porous structure (Steendam et al. 2001). Kim and Park attempted to control 
the porosity at a nanometre scale by crystallising PLA/PLGA blend microspheres 
during solvent evaporation (Kim & Park 2004a). It was found that both PLA and 
PLA/PLGA microspheres exhibited organised nanoporous crystalline structures during 
precipitation which allowed a more sustained drug release over time.
25
1.6 Description of the polymer, poly(lactic-co- 
glycolic acid)
Poly lactic acid (PLA) was first introduced in 1962 in medical sutures because 
of its physical integrity and strength. The combination of poly glycolic acid (PGA) 
monomers with poly lactic acid monomers resulted in poly(lactic-co-glycolic acid) 
(PLGA). PLGA is biocompatible and approved by the Food and Drug Administration 
(FDA).
1.6.1 Polymerisation of PLGA
The word ‘polymer’ originates from the Greek ‘poly’ for many and ‘meros’ for 
parts. By definition, a polymer is a repeat of a basic building block known as 
monomers. When the same monomer forms the long string of covalently bond units, it 
is called a homopolymer, whereas a copolymer contains two or more different 
monomers. The polymerisation of PLGA proceeds by ring-opening linking lactic acid 
and glycolic acid monomers via ester bonds, as shown in Fig. 1.5. Due to its methyl 
side group, PLA exists in an optically active form L-PLA as well as in an optically 
inactive form D,L-PLA. The former is usually preferred for physical and mechanical 
characteristics that will be later described in section 1.6.2.3. The chain is extended to 
any desirable length commonly specified by the molecular weight (MW), or by the 
number of repeat units called degree of polymerisation. The inherent viscosity also 
characterises the degree of polymerisation as the molecular weight influences solution 
flowability. By definition, the inherent viscosity is the ratio of the natural logarithm of 
the relative viscosity to the concentration of the polymer in grams per 100 ml of 
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Figure 1.5. Illustration of Lactide and Glycolide monomers linked via ester bonds by 
ring-opening polymerisation.
1.6.2 Physical and mechanical properties of PLGA
The following section aims to introduce essential notions of physics and 
thermodynamics that will be used during the discussion of results. The last part will 
review the mechanical properties acquired by PLGA microspheres made via w/o/w 
solvent extraction method, and will conclude on the importance of the mechanical 
parameters for a drug delivery system.
1.6.2.1 Molecular mobility of the polymer chain
The degree of molecular mobility of a polymeric chain depends on the steric 
nature of the monomers, as well as the enthalpy of the system. There exist two main 
types of chain motions illustrated in Fig. 1.6. The first refers to main chain 
reorientation known as primary- or a-relaxation. This consists of long-range segmental 
motion of groups of 10 to 15 atoms, a phenomenon which occurs when there is enough
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space and energy. Secondary- or P-relaxation refers to side group rotations occurring at 
higher frequencies and shorter times. Obviously, the kinetic energy and space required 
to move long chain fragments are greater than those necessary for side group rotations. 
In the case of PLGA, the bulky methyl groups of PLA segments undergo side group 
rotations, and at high temperatures, as the heat supplies sufficient thermal energy, 
long-range segmental motions are also initiated (Tice & Cowsar 1984).
Figure 1.6. Illustration o f the a-relaxation or long-range segmental motion (A) and the 
/3-relaxation or side-chain mobility (B) occurring according to the thermal energy 
provided.
At high temperatures, amorphous polymers appear fluid and transparent, but as 
the temperature decreases, they lose their malleability and pliability to become opaque 
and acquire a hard and brittle texture. Directly inspired from their appearance and 
consistency, polymers are said to be in a ‘rubbery state’ at high temperatures, whereas 
low temperatures bring them into a ‘glassy state’. The process, clearly directed by heat, 
is reversible. In thermodynamic terms, heat is a form of kinetic energy that confers to 
the polymer the force necessary to initiate movements. In their rubbery state, the 
characteristic flexible nature of amorphous polymers originates from long-range
A
B
1.6.2.2 From g lassy  to rubbery state
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segmental motion as explained above. In their glassy state, the kinetic energy is so low 
that only low amplitude motions, such as side group rotations, are taking place. As the 
temperature drops, the viscosity increases and eventually, long-range segmental 
motions grind to a halt. Vitrification occurs, rendering the amorphous material as a 
glass. In semi-crystalline polymers, only the amorphous regions undergo vitrification.
1.6.2.3 Definition of the glass transition temperature
The glass transition temperature is defined as the temperature at which a rigid 
or glassy polymer transforms into a softer or rubbery state due to an increase in 
molecular mobility upon heating (devitrification). The time required for the dynamic 
conversion to be completed depends on the experimental heating rate as well as the 
history of the sample. For example, during vitrification, a slow cooling rate contributes 
in delaying the immobilisation of the polymeric chains while providing more time for 
cooperative arrangements to take place. Therefore, the slower the cooling rate, the 
lower the Tg.
The glass transition is most commonly visualised via Differential Scanning 
Calorimetry (DSC) as shown in Fig. 1.7, and it is observed as a relatively abrupt 
change in heat capacity. The temperature of the Tg is defined as the temperature 
corresponding to the point of inflection of the heating curve (Hodge 1994). 
Measurements of the glass transition not only give an insight on the thermodynamic 
capacities of polymers, but they also contain information about structural differences 
between or within samples.
Only amorphous polymers exhibit a glass transition phenomenon, regardless of 
their full or partial amorphous composition. The Tg of PLGA depends on the 
respective mechanical characteristics of PLA and PGA. It is known that D-PLA and L- 
PLA are semi-crystalline because of high uniformity in their polymeric chain hindering 
molecular flexibility, while D,L-PLA is amorphous due to irregularities in its chain 
structure (Tice & Cowsar 1984). On the contrary, PGA lacking the methyl side group 
of PLA is highly crystalline (Ford & Timmins 1989). The ensuing PLA/PGA 
combination allows the production of a wide variety of copolymers with specific 
mechanical states resulting from: the nature of the assembled molecules, the PLA/PGA
29
ratio and the degree of polymerisation. The glass transition temperature of the 
copolymer can be calculated from the Gordon-Taylor equation (1.1) (Hancock & 
Zografi 1994):
wA+kwB
wa, wb: weight fraction of the monomers A and B 
TgA, TgB : Tg of the homopolymers A and B
k : the free volume ratio of the two components under any given condition
Onset 44.93 °C
28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 °C
Figure 1.7. Determination o f the glass transition temperature o f PLGA by following 
the point o f inflection o f the DSC curve. Note the change o f the baseline indicating a 
glass transition event and not a melting or crystallising event.
1.6.2.4 H eat capacity
At constant pressure, the heat capacity is the amount of heat required to change 
the temperature of a substance by 1°C. It is determined by the following equation (1.2):
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1.2
Cp: heat capacity at constant pressure (J/°C) 
q\ heat supplied (J)
T, -  To', difference between the temperature at time ‘t* and the initial temperature (°C or 
Kelvin)
The heat capacity can be visualised in Fig. 1.8 by plotting the heat flow against 
temperature. The heat flow is defined by the temperature supplied per unit time. On the 
basis of a DSC experiment model, the heat flow corresponds to the heat provided to 
the sample in order to align with the temperature applied to the reference pan. As the 
temperature rises, there is an increase in heat capacity reflecting the greater capacity of 
the polymer to absorb heat as it transforms from the glass to the rubber state. While 
heat is being taken up, an endothermic slope illustrates the physical evolution taking 
place over a temperature range with no sudden events. This type of change in heat 
capacity differentiates the glass transition from the phenomenon of melting or freezing 











Figure 1.8. Illustration o f the change in heat flow  over increasing temperature. The 
endothermic slope indicates that the sample exhibits a higher capacity for absorbing 
heat.
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1.6.2.5 Crystallisation and melting of semi-amorphous 
polymers
In order to distinguish the glass transition phenomenon from crystallisation and 
melting, a brief definition of these two processes is given here. For semi-crystalline 
polymers, as the temperature rises above the glass transition temperature, an 
exothermic peak is recorded where the polymeric chains fall into crystalline 
arrangements. This temperature is called the crystallisation temperature, 7c, and it is 
measured at the apex of the peak. By further increasing the temperature, eventually the 
crystal liquefies and an endothermic peak is observed at the melting transition, Tm 
(e.g.: Tm of PGA highly crystalline ~ 230°C; Tm of L-PLA semi crystalline ~ 175°C). 
Crystallisation followed by melting is not always typical of all semi-crystalline 
polymers.
Crystallisation and melting are characterised by heat emitted and absorbed, 
respectively. In each case the heat capacity returns to its initial value once the 
transitions completed (the baseline stays constant before and after the event). This 
particular feature is known as latent heat of crystallising and melting, and is referred to 
as a first order transition. In contrast, during the glass transition the material does not 
recover its initial heat capacity after completion of the transfer. As no latent heat is 
exhibited, it is called a second order transition. Figure 1.9 illustrates a complete 











Figure 1.9. Illustration o f an entire DSC thermograph representing the thermal 
transitions o f a semi-crystalline sample over heating. The first transformation consists 
o f the glass transition, followed by crystallisation and melting.
1.6.2.6 Enthalpy relaxation
At all states, amorphous materials tend towards equilibrium through molecular 
rearrangements. The polymeric structures are said to relax. The completion of the 
molecular relaxation also depends on the environmental temperature and Tg as 
illustrated in Fig. 1.10. At high temperatures, enough kinetic energy is provided to 
bring the chain segments to equilibrium in a short time (stage 1 in Fig. 1.10). As the 
temperature decreases, chain mobility is reduced, and more time is required for the 
sample to return to equilibrium (stage 2). Eventually, the cooperative rearrangements 
become so slow that there is not sufficient time for the sample to relax (stage 3). At 
this point, the experimental cooling rate is faster than the relaxation time of the sample 







Figure 1.10. Illustration o f the time necessary fo r molecular rearrangements or 
internal relaxation to be completed in order to equilibrate with the environment.
By definition, the enthalpy relaxation is the heat content of a chemical system 
returning to equilibrium through changes in atomic arrangement. It is important to note 
that these molecular rearrangements are dependent on the initial atomic conformation 
of the polymeric network, which can be evaluated with the study of physical ageing 
described in the next section. Often, the relaxation time is predicted using 
mathematical models (Hodge 1994; Shamblin et al. 1999), and the maximum enthalpy 
recovery which corresponds to equilibrium is calculated from the following equation 
(1.3):
A H „ = (T g-T )A C p  1.3
AHcc: maximum enthalpy relaxation (J)
Tg: glass transition temperature (°C)
T: experimental temperature (°C)
ACp: change in heat capacity at the glass transition (J/ °C)
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1.6.2.7 Physical ageing
The term ‘physical ageing’ was introduced to distinguish mechanical effects 
from those produced by degradation or polymorphic changes. Ageing characterizes the 
impact of time, temperature and environmental conditions on the material when stored 
below its Tg. The phenomenon of physical ageing is observed as a peak superimposed 
on the glass transition (the enthalpy relaxation peak or overheating peak).
A glassy amorphous polymer in non-equilibrium below its Tg will undergo side 
group rotation. With time, a gradual broadening of the overheating peak is observed, 
concomitant with an increase in the Tg (Fig. 1.11). The progressive reduction of side 
chain mobility is the result of a gain in matrix density due to loss of intermolecular 
space. Lowering the storage temperature increases the enthalpy relaxation due to 
slower molecular motions, and therefore a longer time is necessary for the structure to 
fully relax (Bailey et al. 2002; Hancock et al. 1995; Van den Mooter et al. 1999). The 
storage temperature is often referred to as ageing temperature or Ta. As Ta decreases, 
the molecular mobility diminishes considerably and the relaxation process slows down 
until eventually a temperature where molecular motion is insignificant is reached. In 
order to attain such inactivity, it is necessary to cool the material at least 50°C below 
its Tg, a limit also known as the Kauzmann temperature or Tk (Kauzmann 1948). 
There is a paucity of research dedicated to identifying the stability of drug-loaded 
PLGA microspheres despite its necessity during storage. Mathematical models have 
been developed to predict and fit experimental DSC traces (Andreozzi et al. 2003; 
Cowie & Ferguson 1986).
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Figure 1.11. Illustration o f the molecular relaxation o f a polymer subjected to different 
periods o f physical ageing under constant temperature.
Technically, the ageing potential of a glassy polymer is revealed by comparing 
the first heating peak with the one successive to “quench cooling”, a method of cooling 
so rapidly that molecular relaxation is minimal. The difference between the curves 
superimposed is often referred to as ‘overshoot’ or the ‘overheating’ peak, and its area 
represents the enthalpy relaxation (Fig. 1.12). Modulated DSC was recently proved to 
be capable of isolating the glass transition from the enthalpy relaxation signal without 
quench cooling the sample (Royall et al. 1998; Royall et al. 1999). In this case, the 
glass transition is represented by a reversing signal describing a kinetic event, whereas 
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Figure 1.12. Determination o f the Enthalpy Relaxation o f blank microspheres made 
with low molecular weight PEG A and aged fo r  3 months at 4°C with silica gel (1: first 
heat run; 2: second heat run immediately after quench cooling).
The enthalpy relaxation corresponds to the following equation (1.4):
t 2
AH = \(Cl( T ) - c 2(T))dT 1.4
r,
AH: enthalpy relaxation (J)
ci, cy. heat capacity of the first and second heat runs (J/ °C)
T: experimental temperature (°C)
1.6.2.8 Free volum e
As explained above, the phenomenon of physical ageing corresponds to a 
structural recovery. Therefore the spatial arrangement of the polymeric chains imposes 
a considerable constraint on ageing progress. The entanglement of the polymer chains 
results in a web of a density relative to their length: the longer the chains, the denser 
the network. The mesh is constantly left with spaces in between the chains that are 
waiting to be filled. These volumes are ideal interstices for small chain segments to
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rotate and move relatively freely. The local rearrangements yield structures that are 
successively removed from their previous configuration.
During physical ageing, these spaces are preferentially occupied first. It is 
suggested that the initial rapid relaxation often observed results from relaxing 
molecules revolving in these so-called ‘free volumes’ (Lamarre & Sung 1983). 
Subsequently, the densification of the matrix shifts the glass transition temperature of 
the polymer towards higher values as shown in the previous Fig. 1.11.
1.6.2.9 The mechanical properties of PLGA microspheres
Only a few studies have focused on the mechanical progression of PLGA under 
processing. There are two main systems affecting the copolymer’s Tg during 
microsphere fabrication: the inevitable manufacturing stresses such as solvent removal, 
and supplementary strains, for example due to the additional use of emulsifiers.
During solvent extraction, the polymer precipitates and the microspheres 
harden rapidly. In doing so, the polymeric chains are effectively immobilised without 
time for equilibrium to be achieved (Li et al. 1995). By varying the speed of the 
solvent extraction, the molecular arrangement as well as the relaxation point of the 
polymeric chains will be set in different configurations as illustrated in the previous 
Fig 1.10. The particles are then collected and dried. Unfortunately, the removal of 
water is hard to complete and residual amounts of water often lower the Tg of the 
material since water acts as a plasticizer (Passerini & Craig 2001).
Plasticizers are small molecules soluble in the polymer that ease its chain 
mobility and lower its Tg. The emulsifiers or surfactants added to the primary 
emulsion often operate as plasticizers or anti-plasticizers. Some organic materials, such 
as triethyl citrate or acetyltributyl citrate, have already been identified as plasticizers 
when integrated in PLGA films (Kranz et al. 2000). Modifying the amount of stabiliser 
added to the solution may lead to immiscibility when too high concentrations or too 
large molecules are used (Jeong et al. 2000). In this case, thermal analysis reveals two 
distinct peaks, one belonging to the emulsifier and the other to the polymer, whereas 
only one peak is seen when the blend between the polymer and the emulsifier is 
homogeneous. It is also important to note that the temperature corresponding to the
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glass transition of PLGA microspheres reflects the history of the sample which can not 
be ignored and should be optimized (Yang et al. 2000).
During storage, the hygroscopic nature of PLGA facilitates water adsorption. 
PLGA hydration operates at a rate which is dependant on the water-vapour/copolymer 
affinity, and continues until limitation or saturation is reached (Oksanen & Zografi 
1993). Meanwhile, a significant redistribution of the free-volume occurs within the 
PLGA matrix and increases the chain mobility, thereby lowering the Tg (Hancock & 
Zografi 1994). When finally PLGA microspheres are placed in vitro conditions, chain 
mobility is drastically accelerated with direct exposure to water and elevated 
temperature. In addition, water uptake swells the PLGA matrix, which may undergo 
main-chain relaxation (Sharp et a l 2001). As a result, hydrolysis increases as water 
molecules enter more easily in contact with ester linkages (Deng & Uhrich 2002). 
Degradation products together with the drug are evacuated more rapidly, although in a 
different manner for amorphous and crystalline regions (Pistner et a l 1993). It would 
be advantageous to be able to control the formulation parameters in order to meet the 
physical stability required for a drug delivery system. The importance of achieving 
such a result is not only related to degradation and drug release, but also to the material 
stability during storage.
1.7 D escription of the 9th-10th Fibronectin type 
III dom ain pair, FIII9'-10
1.7.1 Introduction
The cells defining a tissue are physically maintained via a mechanical support 
called the extracellular matrix (ECM). Although the molecular composition of the 
ECM varies from one cell type to another, polysaccharides and glycoproteins comprise 
the majority. These macromolecules provide physical scaffolding and are also involved 
in cell signalling via adhesive recognition sequences (Campbell & Reece 1947). These 
signals orchestrate mechanisms such as cell adhesion, migration, polarisation, 
proliferation and differentiation; in summary, a variety of activities involved in
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embryogenesis, tumour metastasis, angiogenesis, haemostasis as well as other 
biological processes. Cell adherence is one of the most extensively studied ECM 
activities, and the majority of the adhesive proteins interacting with cell-surface 
receptors have now been identified: collagen, thrombospondin, fibrin, fibronectin, 
laminin and vitronectin (Kreis & Vale 1999).
Fibronectin (FN) participates directly in the cell-cell contact by binding to 
ubiquitous cell surface membrane proteins called integrins (Clark & Brugge 1995; 
Stenman & Vaheri 1978). Integrins span the membrane to bind to the cytoskeleton and 
are involved in inside-out signalling (Giancotti & Ruoslahti 1999; Kreis & Vale 1999). 
The key adhesive site in fibronectin is composed of a tri-peptide segment, Arg-Gly- 
Asp, referred to as RGD in single letter code (Pierschbacher & Ruoslahti 1984). It is 
important to note that fibronectin does not hold the monopoly on RGD which in fact 
occurs in numerous ECM proteins as the ligand for several receptors of the integrin 
family (Ruoslahti 1996). Table 1.4 summarises a list of a few ECM proteins and their 
adhesive sites, among which RGD is visibly the most frequent.
ECM proteins Adhesive recognition sequences
FN RGD, DRVPHSRN, LDV, REDV, ID APS, KLDAPT, PRARI
Laminin RGD, LRE, YIGSR, PDSGR, RYWLPR, LGTIPG, IKVAV, RNIAEII
Fibrinogen RGD, HHLGGAKQAGDV
Thrombospondin RGD, VTXG, WSXW
Vitronectin RGD
Collagen type VI RGD
Table 1.4. Some ECM proteins and their adhesive sites.
1.7.2 Structure and function of fibronectin
The fibronectin gene is composed of approximately 50 exons which can 
essentially be separated into three groups according to their notable structural 
homology (Mosesson & Amrani 1980). These three groups of repetitive homologous 
domains are known as type I, II and HI (FNI, FNII and FNUI) (Skorstengaard et al. 
1984). Their translation results in a polypeptide compiling approximately 2100-2400 
amino acids (220-250 kDa). Two FN molecules oriented in an anti-parallel manner are
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united via C-terminal disulphide bonds (An et al. 1992). The flexibility among the two 
subunits enables FN to regulate the accessibility of various binding sites by changing 
conformation (Johnson et a l  1999).
In each subunit, FNI, FNII and FNIII compose more than 90% of the total 
peptides as shown in Fig. 1.13. Among the three types o f module, the FNIII 10th 
domain has been identified with the highest cell adhesion activity (Ruoslahti 1996). 
This discovery led to more substantial characterisation o f adjacent FNIII 10 segments, 
distinguishing the central cell binding domain (CCBD) located on the domains FIII8, 9 
and 10. The architecture of the FIII10 domain consists o f a protruding loop on the p- 
strand which holds the RGD site (Leahy et a l  1996). The FIII9 domain greatly 
enhances 015P1 integrin binding via the “synergy site”, located and separated from the 
RGD site by 35 A (Fig. 1.14) (Nagai et a l  1991). The FIII8 side domain facilitates cell 
adhesion, but it only has a moderate influence (AltrofF et a l  2001). The (X5P1 integrin 
binding activity o f FIII9-10 depends on the maintenance of the secondary and tertiary 
structure of the FIII9-10 pair (AltrofF et a l  2003). The positioning of the synergy site 
relative to RGD is therefore critical for otspi integrin binding.
Fibrin I
Heparin I Collagen Heparin III
RGD
1 l-------- 1
OHM 1 2  * » »
Heparin II Fibrin II
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Figure 1.13. Modular organisation and functional regions o f  a fibronectin monomer. 
The domains reported to have an activity are distinctively designated and labelled with 
the name o f  their associated receptor. The minimal active sequence o f  the recognition
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site o f  the CCBD is indicated above the 10th domain o f F ill o f which it belongs to 
(RGD) (Altrojf 1999).
It should be added that the role of fibronectin has been extended beyond 
integrin binding to include: heparin, fibrin and collagen binding domains, and matrix 
assembly regions. Figure 1.13 illustrates the domains of the FI, FII, and Fill modules 
allocated to these functional regions. Although knowledge of some o f these binding 






Figure 1.14. Topology o f functionally important protruding loops within the FIII9-10 
pair.
The variety of functional sites highlights the importance of the role of 
fibronectin over other ECM molecules. Overall, the protein orchestrates the 
establishment and maintenance of tissues through the control of cell positioning and 
cell growth. In the first case, the spatial arrangement of the cell-matrix necessitates a 
fine regulation of the adhesion of cells to fibronectin and their orientation or even 
mobility when the need arises (Johnson et a l 1992). In the latter case, as the anchorage 
of normal cells is compulsory in order to initiate their proliferation, the key role of 
fibronectin is easily understandable (Kubo et al. 1987). Moreover, close examination
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of the cell-fibronectin activity has shown that the protein is also involved in 
modulating cell differentiation (Adams & Watt 1989). However, it is important to 
remember that in all aspects of cell growth and positioning, integrin receptors play a 
role equally important to fibronectin. The characteristics of adhesion receptors are 
described in the following section.
1.7.3 General features of integrin receptors
Integrins are heterodimeric glycoproteins composed of a  and P subunits which 
are non-covalently bonded but interdependent (Humphries et a l  2003). Figure 1.15 
illustrates the protruding globular head containing the N-terminal parts of both 
subunits, and the C-terminal peptides translocating the cell membrane (Kelly et a l  
1987). This configuration enables integrins to be activated via extracellular ligands but 
also from the inside of the cell (inside-out signalling). In effect, intracellular signals 
can trigger conformational changes, thereby switching the integrin heterodimer from 
the inactive to the active state. However, complete activation o f the heterodimer can 
vary in mode and complexity according to the type o f a  and P subunits associated 
(Hibbs etal. 1991).
Figure 1.15. Schematic drawing 
o f a typical integrin heterodimer. 
Both a  and fa r e  transmembrane 
glycoproteins and cell surface 
expression depends on 
heterodimer formation (Altrojf 
1999). Plasmamembrane
COOH COOH
Eighteen a  and eight P subunits have been listed in mammals so far (Beckerle 
2001). Mutational analyses show that a greater conservation o f the P subunits is 
necessary to ensure normal activity, whereas a  subunits tolerate highly divergent
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sequences (Laflamme et al. 1994). The different active combinations o f the a  and the 
P subunits allow a wide variety of recognition of extracellular ligands (Table 1.5). 
Among the different ot/p heterodimers, eleven have been identified to bind to the 
CCBD of fibronectin (Fig. 1.16). All integrins bind specific ligands according to cell 
type and ECM, and are regulated by downstream signalling events. For example, 
pi subunit is kinase regulated and enters a high-affinity form after dephosphorylation 
(Hannigan et al. 1996).
Figure 1.16. Schematic representation o f interactions between fibronectin and 
integrins. Integrin dimers able to recognize the CCBD sequence are form ed as 
indicated with grey lines connecting the subunits. Fibronectin binding by p  subunits 
assembled with all respective a  subunits is represented by black arrows (Altroff 1999).
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Integrin Cell-matrix ligands
FN LN Col TN VN OPN FBG TSP
a m X X
a 231 X X
a 3 p l X X X X






a 8 p i X ? X X X
a 9 p i X X
alO p l X
a l i p i X
a v p i X X
avp3 X X X X X X
avP5 X X
avP6 X X
avP8 X X X






Table 1.5. Example of ECM ligands and the integrin receptors more or less specific. 
The diversity o f integrin binding interactions offers cells the ability to regulate their 
affinity and therefore response to the signal. Abbreviations: FN, fibronectin; LN, 
laminin; Col, collagen; TN, tenascin; VN, vitronectin; OPN, osteopontin; FBG, 
fibrinogen; TSP, thrombosondin.
1.8 Scope of this thesis
This thesis examines the encapsulation of a mutant 9th-10th type ID fibronectin 
domain pair (FIII9-10) in biodegradable microspheres using a water-in-oil-in-water 
double emulsion-evaporation technique. Wild-type FIDP'-IO promotes cell attachment
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and spreading on binding to aspi-integrin receptors which are common to osteoblasts 
and decidual cells (van der Walle et a l 2002). Since aspi-integrin mediates osteoblast 
differentiation, angiogenesis, tumorigenesis and embryo implantation, FIII9'-10 has 
good potential for use in tissue engineering, anti-cancer and implantation therapies 
(Aplin et al. 1999; Cutler & Garcia 2003). For example, the osteocompatibility of 
PLGA supports the use of F1U9’-10 loaded microspheres injected near osseus wounds 
to promote bone regeneration. In order to counteract potential protein adsorption 
during microencapsulation, surfactants or emulsifiers were added individually to the 
primary water phase. An assortment of five non-ionic surfactants comprising Pluronic 
F68, Tween 20, Tween 80, Triton X-100 and Igepal CA-630, was selected. The 
resulting microspheres were compared to particles made with model stabilisers such as 
PVA andBSA.
Each type of microspheres was evaluated according to its size, morphology, 
and degradation. The encapsulation efficiency, release profile, and biological integrity 
characterised with respect to the protein are discussed in the first results chapter 
(Chapter 3). Despite the fact that each formulation conducted to specific external 
morphologies ranging from highly porous and smooth, to scarcely porous and ridged, 
all release profiles exhibited an initial burst. In order to build a more accurate picture 
of the release phenomenon, microsphere internal and external morphologies were 
visually examined via scanning electron microscope (SEM) and confocal laser 
scanning microscope (CLSM) prior and during in vitro release in Chapter 4. During 
incubation, marked differences of the particles’ surface underlined the importance of 
the polymeric chain mechanical activity. Subsequently, the potential of PLGA 
molecular mobility was further investigated in Chapter 5 with the aim of remodelling 
the surface porosity before incubation and ideally reducing the initial burst. Finally, as 
the significance of PLGA’s thermodynamic properties grew progressively over the 
course of this research, the last results chapter was dedicated to formulation parameters 







FJLLL9'-10 is a 198 amino acid His-tagged P-sandwich domain pair, belonging to 
the IgG superfamily, and it exists as a monomer (ca. 21.5 kDa, pi 8.1). Escherichia 
coli (E. coli) strain DH5a was used for general cloning procedures, and E. coli strain 
BL21 (DE3) pLysS was used for expression of FII19'-10 gene. E. coli strains DH5a 
and BL21 were maintained on Luria-Bertani Lennox (LB) plates (0.5% NaCl, 0.5% 
bacto-yeast extract, 1% bacto-tryptone, 1.5% agar) or in LB liquid (0.5% NaCl, 0.5% 
bacto-yeast extract, 1% bacto-tryptone) and propagated at 37°C. For selection of 
transformed E. coli DH5a, LB media was supplemented with ampicillin (100 pg/ml). 
For selection of transformed E. coli BL21 (DE3) pLysS, LB media was supplemented 
with ampicillin (100 pg/ml) and chloramphenicol (15 pg/ml). Protein expression in 
transformed E. coli BL21 (DE3) pLysS was achieved by further addition of isopropyl- 
p-D-thiogalactopyranoside (IPTG) (0.1 pM final concentration).
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2.1.2 Microsphere related
BSA (1 mg/ml), Tween 20 (MW: 1128, HLB: 16.7), Tween 80 (MW: 1310, 
HLB: 15.0), Triton X-100 (MW: 625, HLB: 13.5), and Igepal CA-630 (MW: 603, 
HLB: 13.0) were all supplied by Sigma-Aldrich Chemical Co. Polyvinyl alcohol 
(PVA: MW: 30 000), and Pluronic F68 (MW: 8 400, HLB> 24) were obtained from 
ICN Biomedicals Inc. Poly(lactic-coglycolic acid) (PLGA) copolymer with a 50:50 
D,L-Lactide/Glycolide molar ratio was purchased from Purac biochem Netherlands. 
Low molecular weight PLGA of -15 000 g/mol had an inherent viscosity of 0.18 dl/g, 
and high molecular weight PLGA of -135 000 g/mol had an inherent viscosity of 0.83 
dl/g. The water was distilled to 15 mO/cm2. All other chemical and solvents were 
purchased from Sigma-Aldrich Chemical Co.
2.2 Synthesis and expression of the protein 
FIII9-10
2.2.1 Preparation of competent cells
Competent E. coli cells were prepared as adapted from Sambrook et al 
(Sambrook et al. 2001). Briefly, a single bacterial colony was picked using a flamed 
loop from an agar plate and suspended in 100 ml of LB for over night incubation at 
37°C while shaking. 1 ml of the over night suspension was transferred to 100 ml of LB 
and agitated again at 37°C while cell growth was monitored to an OD600 of -0.4. The 
solution was then transferred into 50 ml ice-cold tubes, and stored on ice for 10 min 
before being centrifuged at 4000 xg for 10 min at 4°C. The supernatant was carefully 
discarded and the pellet resuspended by gently vortexing in 30 ml of transformation 
buffer (TB) (10 mM HEPES, 15 mM CaCl2, 250 mM KC1, 55 mM MnCl2). The 
suspension was placed back on ice for 10 min, centrifuged again at 4100 xg for 10 min 
at 4°C, and after removal of the supernatant, the pellet was resuspended gently in 8 ml
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of ice-cold TB. Dimethyl sulfoxide (DMSO) was added to a final concentration of 7% 
w/v, and the solution was stored on ice for 10 min prior to aliquoting and snap-freezing 
in liquid nitrogen before storage at -80°C.
2.2.2 Transformation of competent cells
100 pi of competent E. coli cells were mixed with 1 pi of DNA, and incubated 
on ice for 10 to 30 min. The cells were heat shocked for 60-90 seconds at 37-42°C, and 
then transferred back on ice for 2 min. Finally, the cells were plated onto LB agar 
containing appropriate antibiotics, ampicillin for E. coli DH5a and ampicillin with 
chloramphenicol for E. coli BL21 (DE3) pLysS, and incubated at 37°C overnight.
2.2.3 Extraction of the clone by miniprep
Small-scale preparations of plasmid DNA were made using the QIAprep Spin 
Plasmid Kit (Qiagen, Ltd, UK), following the manufacturer instructions. Briefly, a 5 
ml overnight culture of E. coli was harvested and resuspended in 250 pi of buffer PI 
(Tris-HCl, pH 8.0, containing RNaseA, 4 pg/ml). The cells were then lysed by the 
addition of 250 pi of buffer P2 (0.2 M NaOH, 1% w/v SDS) and incubated after gentle 
mixing, for 5 min at room temperature. The lysate was then neutralised in 350 pi of 
buffer N3 (potassium acetate, pH 4.8), and kept on ice for 5 min; the tube contents 
were mixed thoroughly and centrifuged at 12000 xg for 15 min. The supernatant was 
applied to a QIAprep spin column, and subsequently washed with PE buffer (1 M 
NaCl, 50 mM Tris-HCl, 15% v/v ethanol, pH 8.5). DNA was eluted from the column 
with 50 pi of Tris-HCl (pH 8.5) and stored at -20°C. In order to estimate the DNA 
purity, a 5 pi sample was electrophoresed on a 0.8% w/v agarose gel and visualised by 
ethidium bromide staining (4 pg/ml). The yield of DNA was measured by UV 
absorbance at 260 nm using the rule that 1 A26 0 is equivalent to a double stranded 
DNA concentration of 50 pg/ml. To check the presence of the FIEI9'-10 cassette, 0.2 
to 1 pg of DNA was mixed with 5 U of each restriction endonuclease (Nhel and 
HindEH, NEB, UK) and 2 pi 10 x reaction buffer (500 mM Tris-HCl pH 7.5, 50 mM 
MgCh, 150 mM NaCl) in a total volume of 20 pi following digestion at 37°C for 4 h.
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2.2.4 Agarose gel electrophoresis
1 pi of a 5 x loading buffer was added to each 4 pi of DNA sample and loaded 
onto a 0.8% agarose gel made according to the recommendations of Sambrook et al. 
(Sambrook et al. 2001). The preparation was electrophoresed at 5-10 V/cm in 1 x Tris- 
borate-EDTA (TBE) running buffer (90 mM Tris-borate, 2 mM EDTA). DNA bands 
were stained with ethidium bromide (0.5 pg/ml), and visualised on an UV 
transilluminator (ca. 290 nm).
2.2.5 Expression of the protein FIII9'-10
A single transformed colony of E. coli BL21 (DE3) pLysS cells was suspended 
in 100 ml of LB containing 100 pg/ml of ampicillin and 15 pg/ml of chloramphenicol. 
The suspension was incubated over night at 37°C in a shaking incubator. The 
following day, 25 ml of the cell culture was diluted into 1 1 of LB with antibiotics, and 
incubated at 37°C with shaking. Cell growth was monitored to an OD60 0 of 0.6 and at 
this point, protein expression was induced by addition of 1 ml of a 100 mM stock 
solution of IPTG. Following a further 3 h incubation, shaking, cells were harvested by 
centrifugation at 5000 xg for 15 min at 4°C, and the supernatant discarded. The cell 
pellet was resuspended in 4 ml of lysis buffer (50 mM Nat^PC^, 300 mM NaCl, 10 
mM imidazole pH 8) per 100 ml of cell culture to which 1 mg/ml lysozyme was added. 
The cells were allowed to lyse while kept on ice for 30 min. The solution was then 
clarified by centrifugation at 50000 xg for 60 min with the supernatant containing the 
soluble Fm9'-10 filtered before purification.
2.2.6 Protein purification
Purification of the histidine-tagged FIII9'-10 from bacteria cell lysate was 
conducted using nickel affinity chromatography with the protein eluted via a 
concentrated imidazole buffer. The preparation of the nickel-immobilised agarose-bead 
column prior to sample loading involved washing with water and then lysis buffer. The
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filtered bacterial lysate sample was then loaded onto the column equilibrated to allow 
for the protein to bind to its walls. Next, the column was washed with wash buffer (50 
mM NaH2PC>4 , 300 mM NaCl, 50 mM imidazole, pH 8) separating immobilised Hist- 
tagged protein from bacterial lysate contaminants. Immobilised protein was eluted 
from the column with elution buffer (50 mM NaH2P0 4 , 300 mM NaCl, 250 mM 
imidazole, pH 8). Eluted fractions containing protein were monitored by (in-line) UV 
absorption at 280 nm. The homogeneity of the eluted fractions was verified by sodium 
dodecyl sulfate polyacrylamide gel (SDS-PAGE). The imidazole was removed by 
dialysis of the pooled fractions in 1 1 of PBS at 4°C, stirring for 24 h. The 
concentration of the dialysed fractions was measured by A280 values using a calculated 
extinction coefficient of 21620 cm^M 1 (Bouissou et al. 2004). The dialysed fractions 
were then concentrated using an Amicon stirred cell with 10000 MWCO filter, 
aliquoted and stored at -80°C until needed.
2.6.7 Analysis of proteins by sodium dodecyl 
sulfate polyacrylamide gel (SDS-PAGE)
Protein analysis by SDS-PAGE was adapted from Laemmli (Laemmli 1970). 
Protein samples were mixed with 1/3 volume of protein loading buffer (3 x protein 
loading buffer: 47 mM Tris-HCl, 5% v/v P-mercaptoethanol, 3.4% w/v SDS, 20% w/v 
sucrose, 0.01% w/v bromophenol blue, pH 6.8), boiled for 5 min and loaded onto gels 
(5% polyacrylamide stacking layer and 12% polyacrylamide resolving layer) prepared 
according to Sambrook et al. (Sambrook et al. 2001), using MiniProteanin apparatus 
(BioRad, UK). Gels were placed in ‘SDS-buffer’ (196 mM glycine, 0.1% SDS, 50 mM 
Tris-HCl pH 8.3), and run under a continuous amperage of 30 mA per gel, until the 
dye reached the bottom of the gel. Proteins were visualised by staining the gels with 
Coomassie brilliant blue (10% v/v acetic acid, 40% v/v methanol, 0.1% w/v 
Coomassie brilliant blue R-250) for at least 2 h, followed by destaining overnight in 
destain solution (10% v/v acetic acid, 40% v/v methanol). Broad-range protein 
molecular weight markers were purchased from Fermentas.
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2.3 Preparation and analysis of microspheres
2.3.1 Preparation of the microspheres
A water-in-oil-in-water (w/o/w) double emulsion-evaporation technique was 
employed. Aqueous solutions containing 0.5% w/v of PVA, BSA at 1 mg/ml, or 5% 
w/v of non-ionic surfactant (Pluronic F6 8 , Tween 20, Tween 80, Triton X-100, Igepal 
CA-680) were prepared separately. An inner water phase of 90 pi of F1119'-10 at 20 
mg/ml in phosphate buffered saline (PBS), with 5 pi of aqueous solution with 
surfactant or stabiliser, or PBS (control) were injected into 950 pi of oil phase: 
dichloromethane (DCM) containing 5% w/v PLGA, and homogenised at 22000 rpm 
for 15 seconds (IKA Ultra Turrax T18). This primary emulsion was transferred into 40 
ml of water containing 0.5% w/v polyvinyl alcohol (PVA), a requirement for 
microsphere preparation (Rafati et al. 1997), and stirred at 500 rpm for 2 h at room 
temperature (IKA ‘Lab Egg’ RW11). The solvent was subsequently evaporated and the 
capsides were allowed to harden. The microspheres were then harvested by 
centrifugation at 4000 xg for 1 min, washed three times in distilled water, snap-frozen 
in liquid nitrogen and finally lyophilised overnight (Micro Modulyo, ThermoSavant). 
Lyophilised microspheres were kept at 4°C in a sealed container with silica gel. 
Microspheres referred to as blank capsides used PBS as the inner aqueous phase. The 
PVA added to the external aqueous for microsphere preparation phase was not taken 
into account and only the surfactants incorporated in the primary emulsion were 
evaluated in this thesis.
2.3.2 External morphology analysis
2.3.2.1 Scanning Electron Microscopy (SEM)
Approximately 1-2 mg of lyophilized microspheres were evenly sprinkled onto 
a carbon adhesive disk mounted to an aluminium stub. Samples were coated with a
53
thin layer of gold for 3 min in an Edwards Sputter-coater S150B and viewed using a 
JEOL JSM6310 SEM operating at 10 kV, 20°C and with a vacuum of 10“ 5 Torr.
2.3.2.2 Atomic Force Microscopy (AFM)
Atomic Force Microscopy images were performed using a NanoScope nia 
controller, a multi-mode AFM head (Digitial Instruments, Santa Barbara, CA) and a J- 
type scanner. Microspheres were mounted to the AFM magnetic stubs by a layer of 
Tempfix, a thermoplastic adhesive resin. All AFM surface topography images were 
recorded in TappingMode™ operation. Tetrahederal-tipped silicon etched cantilevers 
(OTSP, Digitial Instruments, Santa Barbara, CA) with a nominal tip radius of 
curvature <10 nm and a resonant frequency 200-400 kHz were utilised for imaging. 
Surfaces analyses of the topographical images were undertaken with the in-built AFM 
software.
2.3.2.3 Particle size
Microspheres were suspended in distilled water in a small stirring cell of the 
Malvern Mastersizer X (Malvern Instruments, UK, Ltd), and particle size measured 
using laser diffraction with a range lens of 300 mm, a laser obscurity between 12 and 
25%. The values reported are the volume based distribution, relatively to the mode 
diameter and standard deviation of the particles.
2.3.3 Internal morphology analysis
2.3.3.1 Confocal laser scanning microscope (CLSM)
FIH9'-10 (1 mg/ml) was fluorescently labelled with fluorescein isothiocyanate- 
(FITC-) celite (10 mg) by mixing in 0.05 M NaHCC>3 , pH 8.5 for 2 h. After 
centrifugation, unbound FITC was removed by eluting the supernatant through a PD10
54
column (Amersham Bioscience), equilibrated in Nat^PC^, pH 6.5. The molar ratio of 
label:protein was determined as 1:1 (by A280 and A 4 9 5  values), and the protein 
concentration evaluated using the BCA micro-assay. FITC-labelled FH[9,-10 was 
encapsulated into PLGA microspheres as described above. Briefly, an inner water 
phase of 95 til containing FITC-labelled protein at 10 mg/ml without surfactant was 
added to 950 pi of DCM with PLGA (5% w/v), and homogenised at 22000 rpm for 15 
seconds. This primary emulsion was then transferred into 40 ml of water containing 
0.5% w/v PVA, and stirred at 500 rpm for 2 h to allow solvent evaporation and PLGA 
precipitation. Microspheres were washed, harvested, and dried as described above.
Microspheres were mounted on a slide using Vectashield H-1000 (Vector 
Laboratories, CA, USA) to prevent photobleaching and a coverslip set in place. 
Visualization by CLSM (Olympus Fluoview 500, Japan) used an ion laser set to 
488 nm and 505 nm. A series of 1 pm equatorial sections were collected for the 
microsphere (~ 100 pm diam.).
2.3.4 Polymer structure analysis
2.3.4.1 Storage at selected humidity
Approximately 5 mg of lyophilised microspheres were placed into open 
Eppendorf tubes in a sealed chamber. The relative humidity of the air in the chamber 
was controlled using saturated salt solutions. The saturated salt solution was prepared 
by spreading about 3 mm of dry salt in a shallow beaker and adding water to it in order 
to moisten the salt. The desiccant was selected according to the humidity required. 
Sodium chloride and potassium nitrate were used here to prepare saturated salt 
solutions of 75% and 93% relative humidity, respectively (O'Brien 1948).
2.3.4.2 Dynamic Vapour Sorption
Water sorption/desorption studies of the prepared microspheres were conducted 
with a calibrated DVS-1-system (Surface Measurement Systems Ltd., London, UK).
55
The glass pan was carefully filled with approximately 10 mg of microspheres and 
analyzed against an identical empty glass pan as the reference. The relative humidity 
was set to 0% and was increased in steps of 23.7% up to 95% relative humidity. The 
change in mass of the microspheres (as a function of the dry mass at 0 % relative 
humidity) was recorded at each incremental step. Equilibrium mass, at each relative 
humidity, was determined with a dm/dt of 0.001 %/min. Two sorption/desorption 
cycles were recorded for each sample. Experiments were recorded at 20°C and the 
microspheres used for analysis from each batch were free flowing, rather than 
“compacted”.
2.3A.3 Differential Scanning Calorimetry
DSC plots were obtained using dynamic DSC (DSC 822e, Mettler Toledo). 
Samples were prepared by carefully weighing ~l-2 mg of microspheres into an 
aluminium pan, which was then hermetically sealed. An empty pin-holed aluminium 
pan was used as a reference. Both the reference pan and the sample pan were allowed 
to equilibrate isothermally for 5 min at 0°C. The pans were then heated at a rate of 
10°C/min from 0°C to 85°C, quench cooled to -20°C (in order to eliminate any sample 
history), then heated again to 85°C at 10°C/min. The results were analysed using 
Mettler STAR software, and onset of transition was reported as the corresponding 
glass transition temperature (Hodge 1994).
2.3.5 Protein release and encapsulation
2.3.5.1 Alkaline SDS Extraction method
About 7 mg of dried microspheres were weighed and added to 1 ml of 0.1 M 
NaOH containing 2% w/v sodium dodecyl sulfate (Hora et al. 1990). The solution was 
shaken overnight with an Eppendorf Mixer 5342, Anderman, at room temperature. 
After 5 min centrifugation at 12000 xg, the supernatant was used to estimate the 
protein content using the BCA assay. The reading of the samples was done by BCA
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micro-assay versus the supernatant of blank microspheres of the corresponding batch, 
and always repeated three times.
2.3.5.2 Protein recovery by the DMSO/NaOH/SDS 
method
Approximately 7 to 8  mg of dried microspheres were weighed and added to 1 
ml of dimethyl sulfoxide (DMSO) to dissolve the polymer (Sah 1997). The tubes were 
occasionally hand shaken over one hour at room temperature. 5 ml of 0.05 M NaOH 
containing 0.5% w/v sodium dodecyl sulfate were gently mixed with the solution and 
allowed to stand for 1 h at room temperature. The protein concentration was then 
determined using aliquots of the clear solution (samples vs. blank microspheres) by 
BCA micro-assay.
2.3.5.3 In  v itro  protein release
Approximately 10 mg of dried microspheres were weighed into Eppendorf 
tubes and suspended in 1 ml of PBS at pH 7.4 with 0.02% w/v sodium azide to prevent 
microbial growth. The tubes were placed horizontally without shaking at 37°C for 8  
weeks. At predetermined times points (30 min, 1, 2, 4, 8 , 24, and 72 h incubation; then 
1 week, 2 weeks, 4 weeks and 8  weeks incubation), the samples were centrifuged for 2 
min at 12000 rpm, and the supernatant was replaced with fresh buffer. The 
microspheres were resuspended by short sonication when necessary and placed again 
to incubate. The supernatant collected was analysed to determine the protein 
concentration using the BCA micro-assay. Blank microspheres incubated following the 
same procedure were used as reference against the test samples.
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2.3.5.4 BCA micro-assay
About 25 pi of protein sample was added to 200 pi of bicinchoninic acid 
(BCA) working solution. The plate was covered and left at 37°C for 30 min. The 




The baby hamster kidney BHK-21 fibroblast cell line as well as the chemicals 
and buffer solutions were kindly provided by Dr. H. Mardon (Nuffield Dept, of 
Obstetrics and Gynaecology, Oxford University, Oxford). 5 mg of lyophilised 
microspheres in 500 pi of PBS were shaken vigorously at 37°C for 3 h. The suspension 
was centrifuged (12000 xg, 1 min) and 50 pi of the supernatant retained for analysis of 
the protein concentration using the BCA micro-assay. The remainder of the 
supernatant was used to coat a 96-well flat-bottomed plate following a doubling 
dilution protocol, and incubating the plate overnight at 4°C. The last lane contained 
PBS only as the control, as shown in Fig. 2.1. Baby hamster kidney (BHK) cells were 
passaged the day before the assay as required 104 cells per well (50 pi). On the day of 
the assay, the wells were washed three times with PBS, and non-specific cell binding 
was blocked by addition of 100 pi per well of BSA (10 mg/ml) in PBS for 1 h at 37°C. 
The wells were washed again and filled with 50 pi of serum-free medium then 
incubated at 37°C in 5% CO2 for 30 min.
Meanwhile, the serum-containing medium was aspirated from the tissue culture 
flask. The cells were washed in warm PBS (10 ml), and then detached from the flask 
by addition of trypsin (10 ml) for 5 to 10 min. After centrifugation at 1500 xg for 3 
min and aspiration of the trypsin, the cells were washed in warm PBS, resuspended in 
5 ml of serum-free medium in a 50 ml Falcon® tube, and finally placed in a 5% CO2
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incubator for 10 min (the lid left loose to facilitate gaseous exchange). The cell 
suspension was diluted accordingly to obtain a concentration of 2 x 105 of cells per ml 
and 50 pi added to each well in the 96-well plate, pipetting up and down to ensure 
even distribution. The plate was incubated at 37°C in 5% CO2 for 1 h. The media was 
gently removed, the adherent cells washed with 100 pi of warm PBS, and fixed by 
addition of 100 pi of warm fixative (4% glutaraldehyde, 4% formaldehyde in PBS) for 
10 min at room temperature. The fixative was replaced with 100 pi of 0.1% w/v crystal 
violet and left for 10 min after which the dye was carefully washed off with tap water, 
and with methanol when necessary. Finally, 200 pi of methanol was added to each 
well to solubilise the dye and left for 1 h at room temperature; absorption was 
measured at 570 nm (Dynatec Plate Reader).
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Figure 2.1. Representation o f a 96 wells plate to test cell adhesion. The top 4 rows 
were used to test surfactant A, with surfactant B tested in the bottom 4 rows. In the last 
column, PBS was used as a negative control. The samples to examine were added to 





Examination of the biological activity 
of FIII9-10 encapsulated with non­
ionic surfactants
3.1 Introduction
The encapsulation of bioactive compounds remains a fine art where satisfactory 
drug delivery systems are hard to obtain. The difficulties encountered throughout 
microsphere formulation are complicated and hard to overcome, mainly due to the 
technical limitations imposed at the micron- or nanosize scale. Drug loss, emulsion 
instability, and incomplete or non-existent release are examples of problems being 
investigated, although priority is commonly given to drug instability (Crotts & Park 
1995; Kim & Park 1999; Yang et al. 2001). Indeed, the maintenance of the 
therapeutical agent is the most crucial criteria of drug delivery complexes, failure of 
which may initiate an unwanted immune response. During the double emulsion solvent 
evaporation process, the first emulsion has been reported as the most harmful step for 
the protein conformational stability (van de Weert et a l 2000a).
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Proteins are surface active compounds. During exposure at the water/organic 
solvent interface of the primary emulsion, they tend naturally to orientate their 
hydrophobic regions towards the oily phase (Sah 1999a). The degree of protein 
movement at the interfacial region is closely related to the characteristics of the protein 
itself (Middelberg et al 2000). Its electrostatic capacity, spatial conformation and 
chain flexibility will either limit or favour protein interactions at the water/oil 
boundary (Hunter et a l 1991). These exchanges often result in aggregation as well as 
adsorption of the bioactive compound (Hunter et a l 1990). If the contact is prolonged, 
partial or complete unfolding of the protein can take place. In some cases, the 
consequences of these interactions are irreversible, and denatured proteins are liberated 
from the microspheres (van de Weert et a l 2000a). In other cases, aggregates of 
protein non-covalently bound to the polymeric matrix simply do not diffuse out of the 
microparticles, causing discontinuous release behaviour (Morlock et al 1997).
The addition of an emulsifier and surfactant into the primary emulsion of 
PLGA microspheres has been commonly associated with an increase in drug stability 
as well as high encapsulation efficiency (Yang et a l 2001). It is interesting that 
cyclodextrins have been used to improve protein stability, but no systematic evaluation 
of alternative emulsifiers to poly vinylalcohol (PVA) has been reported to date (Kang 
et a l 2002). In this study, a series of non-ionic surfactants has been selected as 
alternatives to PVA for the encapsulation of FU19'-10 into PLGA microspheres using a 
w/o/w double emulsion evaporation technique. A total of five different types of 
surfactants were incorporated separately to the primary emulsion: Pluronic F6 8 , Tween 
20, Tween 80, Triton X-100, and Igepal CA-630. The main criterion for the selection 
of a particular surfactant was in relation to a non-denaturant effect on proteins.
Microspheres were characterised according to their size and their encapsulation 
efficiency. The effects of the surfactants on the polymeric microspheres were 
investigated by examination of the external and internal morphology by SEM, and also 
by verification of the protein location using CLSM. Finally, the peptide backbone 
integrity of FIU9'-10 was assayed by SDS-PAGE, and the degree of unfolding of 




3.2.1 Preparation of the microspheres
Encapsulation of FU19'-10 was done as described in section 2.3.1 with the help 
of stabilisers and surfactants added to the water phase of the primary emulsion. Briefly, 
the first emulsion consists of 90 pi of FIH9'-10 (20 mg/ml) with 5 pi of emulsifier, or 
surfactant, or water (control) injected into 950 pi of dichloromethane (DCM) with 
PLGA (5% w/v). The list of surfactants selected to encapsulate K1119’-10 comprises: 
Pluronic F6 8 , Tween 20, Tween 80, Triton X-100, and Igepal CA-630. Their main 
physico-chemical properties are compiled in Table 3.1.




Igepal CA-630 600 13.0 300 63-67
Triton X-100 625 13.5 240 63-67
Tween 80 1310 15.0 400-620 75
Tween 20 1130 16.7 370-430 98
Pluronic F6 8 -8400 >24 1 0 0 0 > 1 0 0
Table 3.1. Main physico-chemical properties o f the selected non-ionic surfactants. 
(MW: molecular weight; HLB value: HydrophileAipophile balance value)
3.2.2 Internal structure of embedded microspheres
The preparation of the microspheres for internal morphology analysis was 
undertaken following the methods of Sandor et al. (Sandor et al. 2001). Residual water 
was removed from the samples by incubation in 100% ethanol. Microspheres were 
subsequently washed from ethanol with osmium tetraoxide (OSO4) until complete 
elimination of the alcohol, and embedded in LR White embedding media, a low
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viscosity acrylic embedding medium. After 3 days at 30°C, the hard blocks of resin 
were cut with a glass knife on a Reichert Ultracut-E microtome (Leica, Weim, Austria) 
until the equatorial region of embedded microspheres was reached. Finally, the cut 
blocks were imaged by SEM as described in section 2.3.2.1.
3.3 Results and discussion
3.3.1 Effect of non-ionic surfactants on the 
encapsulation efficiency
Protein loss is known to take place during the secondary emulsion, where 
osmotic potential between the inner water droplet and the outer water phase of the 
embryonic microspheres creates a transfer of drug (Yang et al. 2001). The addition of 
surfactant and stabilisers was expected to ameliorate encapsulation efficiency while 
forming a physical barrier to prevent the escape of the protein. The total fraction of 
FUK'-IO remaining in the recovered microspheres was shown to vary noticeably 
between the surfactants added to the primary emulsion, as shown in Fig. 3.1. In order 
to evaluate the importance of the variations within each formulation, a one-way 
analysis of variance was done on all the populations and compiled in Table 3.2. With 
no added surfactant, large protein losses were observed (-85%), and only slightly 
bettered on the addition of PVA (75%). Similar losses to the PVA were measured 
when using Pluronic F6 8 , Tween 20 and Tween 80. The addition of BSA significantly 
increased encapsulation efficiency (29%), although the presence of BSA, a protein 
itself, would have raised the corresponding reading in the BCA protein assay, 
complicating interpretation. The addition of Triton X-100 or Igepal CA-630 
significantly increased the encapsulation efficiency to over 50%.
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Figure 3.1. Encapsulation efficiencies for FIII9'-10 in PLGA microspheres, expressed 
as the percentage o f the theoretical load (1.8 mg FI I I9'-10 per 47.5 mg PLGA). The 
data represents the mean ± standard error of four independent preparations. The 
primary emulsion included protein and surfactant as indicated below each bar.




Pluronic F68 = = =
Tween 20 = — # =
Tween 80 = = # = =
Triton X-100 # # # # # #
Igepal CA-630 # # # # # # =
Table 3.2. Examination of the variations within encapsulation efficiencies o f each type 
of microspheres. The sign *# ’ indicates when two formulations resulted in significantly 
different encapsulation efficiencies, whereas the sign *= ’ implies the contrary.
For the non-ionic surfactants, encapsulation efficiency could be correlated with 
the low hydrophile/lipophile balance (HLB) values o f Triton X-100 and Igepal CA- 
630. All the surfactants used here have HLB values with the range (13-24) facilitating
66
o/w emulsion. Their hydrophilicity favours a convex curvature towards the water 
phase. The resultant primary emulsion would therefore be inherently unstable and yet, 
despite this, the encapsulation efficiency was significantly enhanced for Triton X-100 
and Igepal than for PVA (/?<0.05), the most commonly reported stabiliser. There are of 
course no HLB values for PVA and BSA and their respective mechanism of 
stabilisation differ from the surfactants. A consensus regarding emulsion stability 
versus encapsulation efficiency clearly must exist since coalescence of the inner water 
droplets inevitably leads to protein loss to the continuous phase (Nihant et al. 1994a), 
but equally clear is that surfactant HLB values are poor predictive markers of 
encapsulation efficiency. It is also interesting to note that, in contrast to Rojas et al., 
the Tween’s® did not improve encapsulation, implying that consideration of the 
protein's physico-chemical properties may be important (Rojas et al. 1999).
3.3.2 Size of the microspheres
Particle size was analysed by light scattering using a Malvern Mastersizer X, as 
detailed in section 2.3.23. The microspheres diameters were measured around 90 to 
130 pm (Table 3.3). These were similar to previously reported values for w/o/w double 
emulsion (van de Weert et al. 2000c), although these measurements vary widely 
(Rojas et al. 1999; Yang et al. 2001). It is interesting to note, that the microspheres 
with the highest encapsulation efficiency (Triton X-100 and Igepal CA-630) yielded 
the largest diameter. This suggests that the presence of protein lodged within the 
matrix may hinder the degree of shrinkage of the polymer.
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Microspheres formulations Mode diameter (pm)
Blank microspheres 97.0 ± 14.2
FU19-10 alone 112.9 ±6.2
Fm9'-10 & PVA 109.3 ±11.7
Fm9'-10 & BSA 103.2 ± 18.4
Fm9'-10 & Pluronic F68 107.0 ± 5.8
FEK'-IO & Tween 20 101.8 ±15.2
Fm9'-10 & Tween 80 92.6 ± 11.5
Fm9'-10 & Triton X-100 125.3 ±6.3
Fm9'-10 & Igepal CA-630 126.7 ± 12.3
Table 3.3. Measured microsphere diameters and their standard deviation (pm).
3.3.3 Impact on the morphology of the 
microspheres
Typically, the surface structure for blank microspheres, or microspheres 
containing FH19'-10 alone and with PVA or BSA, was smooth and highly porous (Fig. 
3.2, A, B, C, and D). The internal view brought further evidence of the porosity created 
by the even distribution of the small water droplets of the inner aqueous phase (Fig.
3.3). Unexpected and marked differences were observed at the surface of microsphere 
containing non-ionic surfactants. Inclusion of Pluronic F6 8  dramatically decreased the 
size and density of pores (Fig. 3.2, E), while the Tween’s® resulted in smooth surfaces 
(Fig. 3.2, F and G). In addition, Tween 80 exhibited numerous cavities (Fig. 3.2, G), 
presumably caused by the bursting of water droplets while hardening. A surprising 
consequence in the use of Triton X-100 and Igepal CA-630 was the appearance of 
elevated surface ridges (Fig. 3.2, H and I).
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Figure 3.2. Representative SEM micrographs fo r  microspheres encapsulating FIII9'- 
10 (unless ‘blank') and including surfactant in the primary emulsion as indicated. A, 
‘blank' microsphere; B, no surfactant; C, PVA; D, BSA; E, Pluronic F68; F, Tween 
20; G, Tween 80; H, Triton X-100; 1, Igepal CA-630 (bar, 10 pm).
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Figure 3.3. View o f the internal morphology o f a blank microsphere made with PBS as 
internal aqueous phase revealing numerous internal cavities.
Microspheres acquire their final shape and morphology while hardening during 
the solvent evaporation process of the secondary emulsion (Jeyanthi et al. 1996; Yang 
et al. 2000). Although polymer precipitation depends mostly on solvent extraction, the 
procedure may also be influenced by interfacial tension caused by the surfactant at the 
water/oil boundary. A correlation could possibly be established between loss of surface 
smoothness and porosity, and surfactant HLB value. When the surfactant presented 
higher affinity towards the water of the inner water droplets (at least HLB >15), it 
would be expected to weakly affect the hardening of the polymer. As a result, the 
microspheres would appear smooth and slightly porous. On the contrary, emulsifiers 
with smaller HLB value (-13) are more hydrophobic and will favour the interaction 
with the polymer. Under these circumstances, the extraction of the solvent could be 
constrained by the presence of the emulsifying agent. External morphologies evaluated 
against the physico-chemical characteristics of each surfactant are compiled in Table 
3.4. The images obtained contribute to the support of this argument. In the case of 
microspheres containing Tween 80, the chaotic surface together with the poor 
encapsulation efficiency suggests emulsion instability.
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Surfactant HLB value Viscosity 
(cps) 25°C
Surface morphology
Igepal CA-630 13.0 300 Ridged, some small pores
Triton X-100 13.5 240 Irregular, some small pores
Tween 80 15.0 400-620 Smooth but with cavities
containing small pores
Tween 2 0 16.7 370-430 Smooth, very few small pores
Pluronic F6 8 >24 1 0 0 0 Smooth, some small pores
Table 3.4. FIII9-10 loaded microsphere surface morphologies compared against 
selected physico-chemical parameters for the non-ionic surfactants
In summary, an increase in the surface rugosity of the prepared microspheres 
may be related to decreasing HLB or, less so, to decreasing surfactant viscosity (Table
3.4). Although previous work has related emulsion viscosity to droplet coalescence 
and internal morphology (Schugens et al. 1994), the mechanism behind surface 
morphology is less clear. The absence of HLB values for PVA and BSA, and their 
distinct mechanisms for emulsion stabilization, make their comparison to the series of 
non-ionic surfactants difficult. However, since PVA was universally included during 
secondary emulsion, it is clear that the surfactant included in the primary emulsion was 
the determinant of surface morphology. To gain further information about the particles 
internal morphology, microtome slicing of microspheres was attempted as described 
by Sandor et al. (Sandor et al. 2001). Unfortunately, the microspheres proved too 
fragile, probably a consequence of their much larger size cf. (Sandor et al. 2001), and 
contrast between the polymer and the embedding resin was poor.
3.3.4 Examination of the in vitro release profiles
Protein release analysis was covered over eight weeks, with a particular 
attention for the first hours of incubation where a high release is generally recorded. 
The results obtained were added over time to obtain a cumulative representation of 
protein release, as seen in Fig. 3.4. Figure 3.5 presents the cumulative release of F1119'-
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10 based on the actual protein loading shown in Fig. 3.1. In Fig. 3.5, it is important to 
note that the microspheres made with Tweens®, PVA and Igepal CA-630 release more 
Flll9'-10 than expected from the encapsulation data. Such discrepancies can 
sometimes be expected since complete protein extraction is difficult, and protein 
efficiency protocols often provide underestimate actual values (Sah 1997).
In all cases, a ‘burst release’ profile for FH19’-10 from the microspheres was 
clearly observed in Fig. 3.4 (Wang et al. 2002); the magnitude of the primary phase 
correlating with the respective encapsulation efficiency. Although all microsphere 
formulations gave rise to a second release phase, only the Pluronic F6 8  microspheres 
provided a phase comparable to the magnitude of its burst release (Fig. 3.4). The 
mechanism of burst release has been shown to occur over a period of microsphere 
remodelling, before an enclosed ‘skin’ develops over the surface preventing diffusion 
out of the internal matrix via surface pores (Wang et al. 2002). It was therefore 
reasoned that burst release from the sparsely porous microspheres in this study would 
be limited. However, this was not the case.
In order to verify that the majority of FIII9'-10 was not adsorbed on the 
particles surface and liberated immediately after starting incubation, FITC-labelled 
F]H9'-10 was encapsulated into microspheres for visualization by CLSM (Fig. 3.6). 
Imaging over sequential equatorial cross-sections showed FITC-Fin9'-10 coating or 
depositing within the internal cavities, the structure of which reflected the internal 
morphology seen by SEM (Fig. 3.3). No fluorescence was seen on the microsphere 
surface, which suggested that F1I19'-10 was indeed encapsulated entirely within, 
although no FITC-Fin9,-10 release characteristic was performed. Therefore, the 
existence of a burst release for lightly porous particles may indicate that the rate of 
protein release was not limited by surface pores. However, the presence of bright areas 
indicating high concentrations of labelled protein revealed the random distribution of 
the drug within the internal cavities. This uneven sharing may have facilitated burst 
release, if water was freely able to reach the localized areas of high protein content.
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Figure 3.4. Cumulative in vitro release profiles fo r  microspheres fabricated with 
different stabilisers in the primary emulsion over an 8 week period, expressed as the 
percentage o f the theoretical load. For clarity, the measurements have been separated 
in three graphs keeping the cumulative release o f microspheres made with FII 19'-10 
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Figure 3.5. Cumulative in vitro release profiles for microspheres fabricated with 
different stabilisers in the primary emulsion over an 8 week period, expressed as the 
percentage of the actual protein loading respective to each formulation (encapsulation 
efficiency).
Figure 3.6. Equatorial ‘slices' o f 1 pm o f a PLGA microsphere (-100 pm diameter) 
encapsulating FITC-labelled LI 119'-10 as imaged by CLEM. Light-shaded areas 
indicate distribution of FITC- FIII9'-10, showing outlines o f and deposition within, the 
internal cavities.
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3.3.5 Evaluation of the FIII9'-10 biological activity
Samples of protein released after three hours incubation were tested by SDS- 
PAGE to assess the integrity of the peptide backbone of FIH9'-10. As seen in Fig. 3.7, 
all bands appeared alongside that for the purified protein and expected MW marker 
(loading and staining differs between surfactants). These results indicated a consistent 
preservation of the protein backbone for all non-ionic surfactants, BSA and PVA.
2 3  4 5 6 7 8 9
18.4
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Figure 3.7. SDS-PAGE gel stained with Coomassie blue fo r  F1II9'-10 collected from  
microspheres during in vitro release. Lane 1, protein marker; lane 2, Ni2+-sepharose 
purified FIII9'-10. The following lanes describe the surfactant added during FIII9'-10 
emulsification: lane 3, PVA; lane 4, BSA; lane 5, Tween 20; lane 6, Tween 80; lane 7, 
Triton X-100; lane 8, Igepal CA-630; lane 9, Pluronic F68.
However, maintenance of FHI9'-10 conformational integrity is equally 
important for (Xspi integrin binding. It has been reported that unfolding of the less 
stable FIII9' domain changes the spatial relationship between RGD and the synergy 
sites (Van der Walle et al. 2002). This disruption has been demonstrated to be critical 
for binding activity (Altroff et al. 2003; Grant et al. 1997). To elucidate the stabilizing 
capacities of surfactants during microencapsulation, the biological activity of the
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protein was evaluated by baby hamster kidney (BHK) cell-adhesion assay. The BHK 
cell attachment test was narrowed to the two most relevant surfactants, Triton X-100 
and Igepal CA-630, against PVA, chosen on the basis of high encapsulation 
efficiencies and promising results (Fig. 3.8). Protein The released was tested after 3 
hour incubation at 37°C biological activity This approach circumvented interpretation 
of data from analytical techniques used to study protein conformational change during 
emulsion with respect to protein efficacy. The BHK cell-attachment assay has been 
previously characterized for the elucidation of FIII9'-10 conformational integrity and 
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Figure 3.8. BHK fibroblast cell attachment to plastic surfaces coated with FIII9'-10 
released after 3 h incubation from microspheres formulated with PVA (circle), Triton 
X-100 (square) and Igepal CA-630 (triangle), expressed as the percentage o f maximal 
attachment recorded for purified (non-encapsulated) FIII9'-10 at concentrations above 
lpM .
For protein recovered from microspheres fabricated with Triton X-100 and 
Igepal CA-630, cell adhesion increased in accordance with the protein concentration. 
Moreover, the cell-attachment percentages were near-equivalent to the cell-adhesion
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obtained for purified FIW-IO (positive control) (Fig. 3.8). For Flll9,-10 recovered 
from microspheres fabricated with PVA, the cell-attachment activity dropped 
unexpectedly to around a third of that for purified F1H9'-10 for concentrations <0.3 
pM. The difference in the mean percentage attachment for PVA and Igepal CA- 
630/Triton X-100 was significant below 0.3 pM (p<0.05). The mean for Triton X-100 
appeared slightly less than equivalent concentrations of Igepal CA-630, but this 
difference was not significant (p>0.05).
The shift in the curve for PVA, with respect to Triton X-100 and Igepal CA- 
630, may imply that a greater proportion of the released FHI9'-10 population did not 
bind the ocspi-integrin with maximal affinity. Possibly, the protein experienced a 
greater degree of unfolding wherein the spatial organization between the synergy site 
and RGD site was perturbed. For Triton X-100 and Igepal CA-630, the curves are 
similar to previously reported attachment data for FIH9-10, with attachment 60-70% 
of the maximum at 0.05 pM and a plateau above 0.2 pM (Altroff et al. 2001). 
However, for Triton X-100, attachment at concentrations >0.3 pM was 80-90% of the 
positive control, indicating that a small proportion of the F1119'-10 population might 
also have experienced unfolding. In summary, the activity of the FIII9,-10 domain was 
not or only slightly altered by the manufacturing process for Igepal CA-630 and Triton 
X-100 respectively, but was lowered for PVA.
3.4 Conclusions
The encapsulation efficiency for FH19'-10 was increased to 50-60% when 
using Igepal CA-630 or Triton X-100 in comparison to a rise of 25% for PVA. 
Unfortunately, the use of HLB as a predictor of protein encapsulation was weak, since 
any such influence was masked by many other factors, not least the protein itself. 
However, microsphere morphology did vary in accordance with the HLB values of the 
surfactants, possibly by alteration of the solvent evaporation process. In particular, 
microspheres made with Igepal CA-630 and Triton X-100 resembled an ‘asteroid’ with 
the appearance of surface ridges. Such surfaces may be useful in the development of 
microspheres with reduced contact area for improved dispersion and flow.
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Low surface porosities did not affect the diffusion of FJH9'-10 from the 
microspheres' internal pores in a ‘burst release’, as may have been imagined. F1U9-10 
released from microspheres promoted cell attachment in a concentration-dependent 
manner. The fact that only Igepal CA-630 and Triton X-100 maintained near-maximal 
cell attachment indicated that the conformation of the relatively unstable FIII9' domain 
was preserved. In effect, of the two domains, FIH9' is conformationally more unstable 
(AG(H2o>=7.2 kcal/mol cf. AG(H2O)=13.0 kcal/mol for the Fill 10 domain (Van der 
Walle et a l 2002)) and would be expected to be involved in any unfolding event 
imposed on FIII9'-10 in the event of adsorption at the w/o interface during 
emulsification. However, FU19'-10 supported a level of cell attachment near-equivalent 
to the positive control when recovered from microspheres fabricated with Igepal CA- 
630 or Triton X-100, but not PVA. In addition, SDS-PAGE indicated no change to the 
backbone integrity. Therefore, the loss of biological activity could be accountable to 
conformational changes, which were especially prevalent during emulsification with 
PVA. In summary, PVA should not necessarily be the ‘first choice’ as the primary w/o 
emulsion stabiliser for protein encapsulation. Instead, non-ionic surfactants should be 
considered, particularly for the maintenance of biological activity of conformationally 





Visualisation of the release of 
encapsulated protein and concomitant 
morphological changes
4.1 Introduction
The utility of PLGA microspheres has been built over characteristics such as 
low toxicity, biodegradability, good drug compatibility (Kitchell & Wise 1985; 
Mathiowitz et al. 1997). Over the years, therapeutic compounds have been formulated 
via microencapsulation as listed in Chapter 1 Table 1.1 (Cleland et al. 1997; Perez et 
al. 2002). Although advantages were offered by PLGA encapsulation, the difficulty of 
controlling drug release was repeatedly reported. In fact, only a few studies have been 
fully dedicated to this problem, despite it being central to drug release systems. This 
likely reflects the complexity in understanding the mechanisms behind water 
penetration and drug diffusion in microspheres. In particular, the burst release 
phenomenon still remains to be investigated conclusively. However, rapid release is 
appropriate for some delivery systems; examples are listed in Table 4.1. In general, the
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burst release phenomenon is undesirable and its attenuation has been sought. The most 
promising techniques involve either applying the physico-chemical characteristics of 
the polymer, or physical hindrance through surface pores via surface coating (Lee et al. 
2002). With regards to the former, modifications of the polymer backbone have been 
used to alter the matrix structure, drug distribution, polymer degradation and 
drug/polymer interaction (Pistel etal. 2001).
Situations conducive to burst release Situations inappropriate for burst release
from microspheres from microspheres
♦Wound treatment (immediate relief ♦ Local, systemic toxicity or irritation
followed by a diminishing need for drug) arising from high drug concentrations
♦ Pulsatile delivery in vaccination ♦ Elimination of drugs with a short half-
life in vivo
♦ Targeted delivery followed by a ♦ Economically and therapeutically
triggered burst release wasteful of drug
♦ Encapsulation of flavours ♦ Shortened release profile (require more
(organoleptics in the food industry) frequent dosing)
Table 4.1. Applications wherein burst release may be advantageous or detrimental 
(Huang & Brazel 2001).
Unfortunately, existing techniques developed to attenuate burst release include 
additional costly steps such as polymer grafting, and even then may not ensure a 
predictable or controllable release (Pistel et al. 2001). Consequently, research must 
aim to properly understand the drug release mechanism. In an attempt to fulfil this 
objective, new methods of study have here been designed to visually examine the drug 
release correlated to morphological changes in microspheres. In these investigations, 
particles were fabricated with the same stabilisers and methodology as described in the 
previous chapter. Briefly, FHI9'-10 with and without PVA, BSA, Pluronic F68, Tween 
20, Tween 80, Triton X-100, Igepal CA-630, was added to the primary emulsion, and 
after homogenisation transferred to a hardening tank containing PVA (secondary 
emulsion). Particles were harvested and lyophilised as before. Microspheres were 
subjected to cryo-fracture SEM in order to visualise their internal morphology.
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Microsphere external morphology was also observed by normal SEM following 
incubation in aqueous buffer over time. The external and internal morphologies were 
correlated to the protein release, visualised in real time using CLSM for microspheres 
loaded with MTC-labelled JHT119'-10 (without surfactant) at 37°C.
4.2 M ethods
4.2.1 Internal morphology by cryo-fracture SEM
A cup-shaped sample holder was filled with a suspension of microspheres in 
distilled water and covered by a thin rectangular sheet of scratched aluminium. The 
sample holder aperture was sealed by anchoring each end of the aluminium rectangle 
to a piece of sticky carbon adhesive disc. The whole apparatus was turned upside down 
to avoid the microspheres sinking to the bottom of the sample holder, and then plunged 
into slushy nitrogen. As quickly as possible, the sample holder was introduced into the 
cryo-preparation chamber attached to the SEM (JEOL JSM6310 SEM). The cryo- 
preparation chamber maintained the sample under vacuum at a low temperature (- 
165°C). The scratched aluminium rectangle was then removed with a cooled blade 
causing fracturing of the ice at the sample surface. The sample was then transferred 
into the SEM chamber and onto a cold stage at -170°C. The sample was observed at 
low kV while the stage temperature was raised to -80°C to allow the ice to slowly 
sublime and the fractured microspheres to be revealed. Transferred back into the 
preparation chamber, the microsphere sample was sputter coated with a thin layer of 
gold for 3 min and finally returned to the SEM chamber where images were obtained 
at 10 kV.
86
4.2.2 Real time observation using CLSM and 
microwells
Microspheres with FITC-labelled FIII9'-10 without surfactant in the primary 
emulsion were fabricated as described in section 2.3.1. The microspheres were 
immobilised in microwells for real time observation by CLSM. Microwells were 
micromachined, as shown in Fig. 4.1, into a 10 mm square polycarbonate (‘Cobex’) 
piece at the Laser Micromachining Centre, Institute of Bioelectronics & Molecular 
Microsystems, University of Wales, Bangor, UK. Three cubic wells of 150 i^m square 
were maintained in sink conditions by inlet and outlet channels on either side of each 
well.
A single microsphere (ca. 100-150 i^m diameter) was placed manually in each 
of the three wells, covered and sealed with a coverslip and plasticine. The 
microchannels were connected to a needle and a peristaltic pump, and fed with fresh 
PBS buffer, warmed to 37°C. CLSM imaging was performed as described in section 
2.3.3.1. The polycarbonate device was left in a solution of 50% ethanol for five 
minutes between each use in order to wash away any residual protein or particulates.
a
■ ^ “ 7  C_
cross-section b = 30 jim
Figure 4.1. Sketches o f the polycarbonate piece where each o f the three cubic 
microwells are connected to microchannels on either side. The channel’s depth is 
equivalent to the cube’s side (a=150 pm).
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4.3 Results and discussion
4.3.1 Examination of the internal morphology of 
microspheres
Sandor et al. demonstrated that the internal structure of the microparticles 
influences the release mechanism for microspheres with high loadings wherein protein 
diffusion follows the high density of interconnecting channels (Sandor et al. 2001). 
Other workers have used this hypothesis as a means to explain the release profiles they 
observed in their study (Blanco & Alonso 1998; Kim & Park 2004a). It is indeed 
reasonable to believe that a dense inner labyrinth of cavities and channels will enhance 
the time necessary for the drug to reach an exit hole, whereas few big cavities are more 
likely to provide an easy and fast access to outer pores. According to Florence et al., 
the internal morphology is dependent on the stability of the primary emulsion of the 
w/o/w solvent extraction method (Florence & Whitehill 1981). Three categories of 
internal structure have been defined as microsphere, multivesicular structure, and 




Figure 4.2. Illustration o f the three main types o f internal structure fo r  particles 
fabricated via w/o/w solvent extraction method (Florence & Whitehill 1981).
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‘Microspheres’ may be defined by numerous internal cavities interconnected or 
not (Fig. 4.2). In this case, a highly stable primary emulsion is necessary to retain its 
conformation and resist the mechanical stresses applied throughout the secondary 
emulsification. If a less stable primary emulsion is used, the weaker interface promotes 
the coalescence of the inner water droplets. A non uniform size distribution of inner 
cavities is evidence of poor primary emulsion stability. This typically defines the 
structure as ‘multivesicular’. Finally, very unstable primary emulsions lead to 
complete coalescence of water droplets, forming a single large cavity occupying the 
full space of the particle called ‘microcapsule’.
Since the internal morphology may affect drug release, all microparticles 
(blank, FIH9'-10-loaded with and without stabilisers) were subjected to cryo-SEM. 
This novel method enables arbitrary fracture of particles embedded in ice and was 
found to be highly efficient with respect to microtome sectioning. Representative 
images of fractured particles are shown in Fig. 4.3. For each formulation, the 
microparticles were sorted in Fig. 4.4 according to the classification proposed by 
Florence et al. (1981). Table 4.2 compiles the classification from Fig. 4.4 since a 





Figure 4.3. Images o f cryo-fractured microspheres containing FIII9'-10 with BSA (A), 
and FII19'-10 with Triton X-100 (B). The random fracture provides an exceptional
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collection of sections o f the particles offering to sight apex, latitudinal and equatorial 
regions. Note that the internal morphology can be clearly distinguished from the ice.
The cryo-SEM analysis suggested that the stability of the primary emulsion 
varied with surfactant type added. However, defining a trend between the physico­
chemical parameters of the surfactants added and microsphere internal morphology 
was complicated by the use of non-ionic surfactants and triblock copolymers. For 
instance, microparticles made with either Pluronic F68 or Igepal CA-630 exhibited a 
multivesicular structure even though Pluronic F68 has a much higher HLB value (>25) 
than Igepal CA-630 (-13).
The internal morphologies observed contrasted against the trend suggested in 
Chapter 3 Table 3.4 where surface rugosity was reported to enhance with a decrease in 
surfactant HLB values. This could be due to the heterogeneous mechanism of solvent 
extraction. In effect, during the secondary emulsification, the surface of the 
microparticles is formed instantly, whereas the internal structure materialises at the 
pace of solvent extraction-evaporation. The slow precipitation of internal regions 
allows for coalescence to take place if the stability of the inner water droplets can not 
be sustained. Subsequently, the external morphology may represent polymer 
imprinting by the stabiliser or surfactant, whereas the internal morphology may reflect 
interfacial stability within the time frame allocated by the PLGA hardening process.
HLB values should not be relied upon for the selection of non-ionic surfactants 
for use in microencapsulation. This factor may help in predicting the stability of more 
simple emulsions, but it has been proven to be irrelevant in this case. A recent study by 
Mohamed et al. shows additional evidence of contradiction between emulsion stability 
and inner morphology (Mohamed & van der Walle 2006). It is also suggested that 
results are likely to be specific to the formulation parameters, and therefore, 





Inner structure classification (Fig. 4.4)
Blank microspheres microsphere
Fm9'-10 microsphere
FHI9,-10 & PVA microsphere
FHI9'-10 & BSA microsphere
FH39'-10 & Pluronic F68 multivesicular structure
Fm9-10 & Tween 20 microsphere, multivesicular structure, microcapsule
FIII9'-10 & Tween 80 microsphere, microcapsule
Fm9’-10 & Triton X-100 microsphere
Fm9’-10 & Igepal CA-630 multivesicular structure
Table 4.2. Variety of internal morphologies obtained with respect to the primary 
emulsion formulation, and analysed by cryo-SEM images from Fig. 4.4.
Finally, the internal morphologies were compared against the in vitro release 
data presented in Chapter 3 (Fig 3.4). It was found that none of the three types of 
structure could be correlated to a particular release profile. In addition, a burst release 
was observed for all particles regardless of their inner morphology. These findings 
would appear to contradict previous data by Sandor et al. suggesting a delay or 
attenuation of burst release with differing internal morphologies. For the microspheres 
fabricated here, the internal structure was not the predominant factor controlling drug 
release. However, it is important to note that the size and drug encapsulated between 
this and other studies are very different, highlighting the important of a case-by-case 




FIII9-10 & PVA FIII9-10 & BSA FIII9-10 & Tween 20
FIII9-10 & Tween 80 FIII9 -10 & Triton X-100
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Multivesicular structure
FIII9-10 & Pluronic FIII9 -10 & Tween 20 
F68
Microcapsule
FIII9 - 10 & Tween 20 FTII9 -10 & Tween 80
K B |
Figure 4.4. Fractured particles imaged by cryo-SEM and grouped by type o f internal 
morphology in accordance with the classification proposed by Florence et al.: 
microsphere, multivesicular structure, and microcapsule (bar: 10 pm).
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4.3.2 Transformation of surface morphology 
during incubation
Considering the passivity of the internal structure upon protein release, it was 
considered that the external surface may play a central role in the drug release profile. 
In order to reproduce the chain of events that presumably influence the particle 
surface, microspheres fabricated with FIH9,-10 (but without surfactant) were incubated 
as described during an in vitro release protocol (Chapter 2.3.5.3). After removal at the 
predetermined time points, the microspheres were air-dried and imaged by SEM. The 
change to microsphere surface morphology could then be monitored with time, as 
shown in Fig. 4.5.
A transformation of the surface structure persistently took place over time, with 
a particular emphasis within the first hour of incubation. The ridges covering the entire 
surface of the dried microspheres disappeared within 30 minutes of incubation (Fig. 
4.5). This surface smoothing has been previously described and suggested to be due to 
the swelling of the PLGA matrix upon hydration (Schlapp & Friess 2003). While water 
penetrated the channels of the polymeric matrix, chain elasticity presumably 
counterbalanced the pressure created by the rapid intake of water. Inherent flexibility 
may accommodate stretching of the outer surface eventually erasing surface ridges 
within a surprisingly short time. The magnitude of the response could have been 
predicted due to the additional effects of elevated temperature and plasticization of 
water. Temperatures above the glass transition temperature of the amorphous polymer 
are known to greatly enhance the polymer chain mobility (Tg of PLGA microspheres 
fabricated was 29.9°C < 37°C). Also, the plasticizing action of water will facilitate 
PLGA hydrolysis and further decrease the microspheres’ Tg as the polymer chains 
shorten.
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Figure 4.5. Visual examination o f the surface changes over time for microspheres 
containing FIII9'-10 alone and maintained under typical in vitro release conditions. 
The pictures on the left show an overview o f the spheres ’ morphology. The images on
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the right reveal details o f the surface. The times indicated on the bottom-left comers 
correspond to the duration of incubation. ‘Time 0 3 microspheres were imaged 
immediately after lyophilisation.
Surface remodelling was most evident for those particles which floated in the 
aqueous buffer and presented the particularity of having one portion exposed to the air, 
and a second exposed to the water. In effect, surface alteration was localised to region 
directly in contact with water. The ‘cap’ emerging from the water could be easily 
distinguished from the lower section of the particles as it would conserve the original 
surface morphology of lyophilised microspheres.
From the submerged region of the microsphere, the surface displayed a 
smoothing effect with a progressive diminution in size and presence of external pores. 
This may have been due to surface swelling and PLGA chain mobility. However, near 
complete closure of the pores was decisive between four hours and one week 
incubation (Fig 4.5). At the same time, a film linking the floating particles developed 
at the air/liquid interface, as shown in Fig 4.6. It is difficult to unambiguously 
characterise the nature of this film by visual examination only. It was thought that the 
film could consist of either surface protein or polymeric residues homogeneously 
bridging the ‘caps’ of the floating microparticles. In the latter case, the film would be 
indicative of a high degree of molecular mobility among polymeric fragments and 
external PLGA chains. During this process, exit holes may have been remodelled to 
near disappearance.
This assumption is not incompatible with that by Wang et al., who observed a 
similar closure and loss of external pores within the first 24 hours of incubation (Wang 
et al. 2002). They suggested that the pores were obstructed from within by PLGA 
fragments from polymeric degradation. This would require free diffusion of 
degradation products immediately after immersion. However, numerous studies 
investigating the mechanisms of polymer degradation and erosion demonstrate that 
PLGA microspheres degrade via bulk erosion (Burkersroda et al. 2002; Husmann et al. 
2002). This phenomenon is characterised by a delay in mass loss, which would 
contradict the interpretation by Wang et al.
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Figure 4.6. View from above o f the polymeric film  linking the ‘caps’ o f floating 
microspheres containing FIII9'-10 alone after one week o f incubation.
It is important to note that surface remodelling never led to complete 
disappearance of external pores. Therefore, diffusion of water/drug between the bulk 
microspheres interior would still be possible, although physically restricted. In order to 
evaluate the corresponding water and drug mobility during microsphere immersion, the 
SEM images were compared against the protein release as shown in Fig. 4.7. A 
complicating consideration here was that it was difficult to undoubtedly correlate the 
reduction of number of exit holes with a decrease in protein release since the 
encapsulated drug reservoir was itself lost during release. However, it seems 
reasonable to believe that the quantity of exit pores should determine the protein 
diffusion rate.
This assumption has been recently examined by Ethezazi et al. who 
demonstrated via computational simulation that limited access contributed in obtaining 
a first order release rate (Ehtezazi et al. 2000). Following on from this model, the 
microspheres formulated here with Tween 20, Tween 80, Triton X-100, and Igepal 
CA-630 should have experienced a longer and slower protein release, since these 
microspheres exhibited small or few external pores (Chapter 3, Fig. 3.2). However, all 
of these formulations displayed a burst release profile (Chapter 3, Fig. 3.4). In order to 
understand the survival of the burst release, microsphere surface analysis was 














surfaces were perforated. In the case of the particles fabricated with Tween 20, Tween 
80, Triton X-100, and Igepal CA-630, this porosity would appear to have been 
sufficient to allow for the initial burst release to proceed. A more thorough 
understanding of the release mechanism versus control by external porosity was 
therefore sought and real time observation of protein release was conducted.
7 n 








Figure 4.7. Evolution o f the protein release with respect to the external morphology o f 
microspheres containing FIII9'-10 without surfactant and maintained under similar in 
vitro release conditions.
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Figure 4.8. External morphology o f all microspheres after 30 minute incubation at 
37°C. All microparticles were loaded with FIII9'-J0 unless blank (A). Surfactant or 
stabiliser were added to the primary emulsion as indicated: B, no additional 
surfactant; C, PVA; D, BSA; E, Pluronic F68; F, Tween 20; G, Tween 80; H, Triton X- 
100; I, Igepal CA-630.
4.3.3 Real time observation of protein release
Studies of protein release are generally based on the analysis of the solution of 
incubation. In order to build a more accurate picture of the release phenomenon, real 
time observation was operated via CLSM imaging for microspheres immobilised in 
microwells and loaded FITC-labelled protein. This novel device was designed to
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ensure sink conditions during continuous imaging. Although this technique was useful 
for the observation of release of a small organic compound in a study led by 
Messaritaki et al., it appeared that the nature of the drug loaded played an important 
role in the quality of the pictures obtained (Messaritaki et al. 2005). In the present 
work, the main difficulty consisted in the fluorescence generated on the walls of the 
wells. It was thought that tagged proteins had adsorbed to the polycarbonate walls of 
the wells during release, thereby complicating image analysis as demonstrated in Fig. 
4.9. Clear visualisation of protein release failed even with prior wash of the microwells 
in ethanol. In addition, a mirroring effect from the walls impeded distinction between 
proteins still encapsulated and protein released.
Figure 4.9. Representative microscopic view o f the microwells (A), and comparative 
confocal imaging o f empty wells (B) with wells occupied by a single microsphere 
loaded with FITC-labelled FIII9'-10 (C). Images interpretations were complicated due 
to the fluorescence generated on the walls o f the empty wells (B) added with the walls’ 
mirroring effect (C).
An alternative technique was therefore used where a few microspheres were 
sprinkled onto a normal glass slide which was then mounted on a thermo-sensed slide 
holder generating a constant temperature of 37°C. The microspheres were then 
submerged in PBS warmed to 37°C. The addition of PBS was designated as time zero 
for the experiment. In order to keep the microspheres immobilised in one place for 
imaging, no buffer was added or removed during imaging. Therefore ideal sink 
conditions could not be maintained and may have influenced the data. Nevertheless, 
protein release was recorded over 65 minutes; Fig. 4.10 showing cross-section images
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(1 pm thick slices) of the apical (a), latitudinal (b) and equatorial (c) regions of the 
same microsphere over time.
Time 0 
a
After 5 minutes 
a





After 40 minutes 
a
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Figure 4.10. Real time observation o f FITC-labelled FIII9'-10 release during 
incubation in PBS at 37°C over 65 minutes (a: apical section; b: latitudinal section; c: 
equatorial section).
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Initial images (time zero) showed a heterogeneous distribution of protein. 
Regions of higher fluorescence intensity may indicate higher protein concentrations, 
although this technique is only semi-quantitative and calibration was not performed. 
Nevertheless, over the 65 minute incubation, the fluorescence faded considerably 
suggesting loss of encapsulated protein. The protein loss seen over this period may 
represent the burst release seen in vitro, this protein fraction being soluble and 
noticeably mobile. Clearly, a degree of fluorescence remained following 65 minute 
incubation and may either correspond to protein entrapped in the internal pores, or 
within the PLGA matrix, or insoluble (aggregated protein). To distinguish between 
either three of the possibilities would have required extension of observation to around 
4 hours, when the release plateau is observed in vitro. Unfortunately, this was not 
practicable. Also, considering the static nature of the immersion here, a more rapid 
release profile may be anticipated in vivo wherein clearance of released drug would 
maintain sink conditions.
4.4 Conclusions
Visualisation of microsphere morphology was used to gain further 
understanding concerning the mechanisms of protein release, particularly the initial 
burst release. The internal morphology analysed by cryo-SEM contrasted against in 
vitro release profiles obtained previously in Chapter 3 such that no correlation could be 
discerned. Internal morphology did not influence the burst release phenomenon. 
However, SEM and cryo-SEM imaging did show the influence of emulsion stabilisers 
upon microsphere morphology. A decrease in the emulsion stability of the primary 
emulsion yielded a shift from ‘microsphere’, to ‘multivesicular structure’, to 
‘microcapsule’ classification of the interior. Unfortunately, the HLB values of the 
surfactants could not predict the integrity of the primary emulsions during hardening. 
Probably, the secondary emulsification of the w/o/w technique comprises additional 
stresses which may affect considerably the stability of the emulsions.
Although the internal structure could not circumvent the initial burst release, 
real-time confocal imaging showed that burst release was due to drug mobility and
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accessibility to the release medium, and therefore controlled by the external porosity. 
Unfortunately, while protein release declined following the first hours of incubation, 
this could not be correlated unambiguously to closure of the external pores observed 
via SEM imaging. The disappearance of exit pores was accompanied by an overall 
smoothing of the microsphere surface. Surface remodelling was probably a result of 
PLGA chain mobility induced by temperature elevated above the Tg of the 
microspheres, and the plasticization effect of water. The molecular rearrangement did 
not however lead to total collapse of the spherical structure. This fundamental property 
of amorphous PLGA polymer could be exploited as a means to reduce surface porosity 




The influence of surfactant on PLGA 
microsphere glass transition and 
water sorption
5.1 Introduction
The addition of surfactant to the primary emulsion of the w/o/w solvent 
extraction process has proved in some cases to have beneficial effects (van de Weert et 
al. 2000b) but in others to be detrimental, or have no effect (Deng et al 1999). There is 
a paucity of research dedicated to dissecting the underlying molecular interactions 
between surfactant and drug/PLGA in microsphere formulations. One reason may be 
the difficulty in elaborating appropriate protocols when working at a sub-micron scale. 
However, it is possible to assess the overall physical properties of PLGA microspheres 
and indirectly determine the effects of the surfactant.
The mobility of the PLGA chains in their glassy state (Li et al. 1995) will 
depend on how any additive, either drug or surfactant, interacts with the polymer 
during solvent evaporation and following lyophilisation. In order to characterise the
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amorphous nature of the polymer and to investigate its physical properties, the glass 
transition temperature, Tg, becomes a critical parameter. The examination of the 
mechanical stability of microspheres at increasing relative humidity is also important 
in the assessment of shelf-life storage times. Since water is known as a plasticizer for 
amorphous polymers such as PLGA, the result of storage at high relative humidity may 
directly influence microsphere morphology. The ability to controllably reduce the 
number of exit pores at the microspheres surface would be of considerable interest 
with respect to control of drug release. Wang et a l also showed that after 24 hours 
immersion in water, a ‘skin’ may envelope the outer surface of the microspheres 
(Wang et al 2002). The concomitant loss of external pores was suggested to result in 
the subsequent termination of the period of burst release. In a similar manner, it seems 
reasonable that the closure of surface pores will attenuate drug release. Shaping the 
microsphere surface subsequent to fabrication-lyophilisation, however, may provide a 
more novel route.
In this study, FIH9'-10 was encapsulated with PVA and Triton X-100 as 
stabilisers of the primary emulsion. The objective was to investigate the influence of 
water vapour and surfactant molecules on the mechanical integrity of amorphous 
PLGA microspheres. The storage stability of microspheres was challenged through 
exposure at ambient humidity and 75% relative humidity, and the parameters 
influenced by the residual amount of surfactant determined. Vapour sorption was 
utilised to investigate and demonstrate the hydrophilic nature of each particle 
formulation. The physical and mechanical stability of the polymer were subsequently 
tested to reveal PLGA chain mobility using DSC. Surface modifications caused by 
chain flexibility were expected and pore reduction was examined by atomic force 
microscopy (AFM). Topographical imaging of the surface of microspheres maintained 
at increasing relative humidity provided an insight into the plastic nature of the PLGA. 
Protein location and distribution within microspheres exposed to high humidity was 
verified with CLSM. Finally, the potential of surface remodelling with respect to 
controlling burst release was investigated and discussed.
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5.2 Methods
5.2.1 Storage at selected humidity
Samples of microspheres were exposed to humidity following the protocol 
detailed in section 2.3.4.1. The saturated salt solutions were selected to obtain relative 
humidities of 75% and 93% when left at room temperature. Sodium chloride and 
potassium nitrate were used to prepare the saturated salt solutions of 75% and 93% 
relative humidity, respectively (O'Brien 1948).
5.2.2 Atomic force microscopy (AFM) imaging 
under controlled environmental condition
Atomic Force Microscopy surface topographical images were recorded in 
TappingMode™ operation as described in section 2.3.2.2. In order to maintain the 
sample at required humidity, the optical head was sealed off from the ambient 
environment. Controlled partial vapour pressures were introduced into the chamber 
through an in-let tubing while a humidity probe deeply inserted recorded the relative 
humidity during scanning. It was ensured that neither tubing nor probe would interfere 
with the piezoelectric tube or the reflected laser beam. The starting relative humidity 
was set to 20% and increased progressively to 40%, 55% and 70% relative humidity 
while imaging surface remodelling. At each step, the particles were allowed to 
equilibrate for 4 h, although real-time recording enabled to determine that surface 
transformations would cease after the first 20 minutes.
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5.2.3 Visualisation by CLSM of protein 
distribution in microspheres exposed to high 
humidity
FITC-labelled protein was encapsulated without surfactant in PLGA 
microspheres as detailed in section 2.3.3.1. Immediately after lyophilisation, a few 
microspheres were evenly sprinkled onto glass slides, and the initial distribution of the 
labelled protein was observed with confocal microscopy as described in section 
2.3.3.1. The same slides were then kept at 93% relative humidity for 1 and 24 hours, 
and the protein was again localised by confocal imaging. The even spreading of the 
polymeric particles was necessary to avoid irreversible microsphere aggregation, 
which would render visualisation difficult.
5.3 Results and discussion
5.3.1 Sizes of microspheres
The mode diameter of the microspheres ranged from 97.0 pm to 125.3 pm 
diameter as presented in Table 5.1. As already noted in Chapter 3, the addition of 
Triton X-100 in the internal water phase led to the formation of larger microspheres. 
Possibly, this change resulted in a high viscosity of the primary emulsion, and 
therefore larger droplet size, as previously reported in the literature (Yang et al. 2001).
I l l
Microsphere formulations Mode diameter (pm)
Blank microspheres 97.0 ± 14.2
FIII9'-10 alone 112.9 ±6.2
Fm9'-10 and PVA 109.3 ±11.7
FU19-10 and Triton X-100 125.3 ±6.3
Table 5.1. Size distribution measurements of microspheres (± standard deviation).
5.3.2 Evolution of microspheres hydrophilic 
properties
The change in mass of a sample upon water uptake is a highly sensitive way of 
investigating the hydrophilic nature of materials as well as the type of water vapour- 
material interaction (Buckton & Darcy 1996). Moisture sorption profiles for 
microspheres containing KLLL9'-10 with and without surfactant in the primary emulsion 
are shown in Fig. 5.1. The profiles in Fig. 5.1 show no discemable differences between 
blank microspheres and microspheres containing FHI9,-10 alone over all relative 
humidities tested. The water sorption-desorption profile for microspheres containing 
PVA and FH[9'-10 was poorly discemable from blank and FIII9'-10-containing 
microspheres until a relative humidity of 95% was reached. On the other hand, the 
profile for microspheres containing Triton X-100 and FIII9'-10 was noticeably 
different above a relative humidity of 45%. Considering that the diameter size of all 
particles did not vary significantly, the hydration capacity could not be correlated to 
surface area. This suggested that microspheres containing Triton X-100, and to a lesser 
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Figure 5.1. Change in mass o f microspheres over increasing relative humidity. The 
water uptake was recorded during sorption (solid lines), and the water loss was 
inversely sampled during desorption (dotted lines). Symbols: microspheres containing 
PBS (circles), FIII9'-10 (up triangles), FIII9'-10 and PVA (squares) and FIII9'-10 and 
Triton X-100 (down triangles). Error bars (smaller than symbols) represent the 
standard deviation.
It is known that stabilisers, when used in the continuous phase of the secondary 
emulsion, adsorbs on to the microsphere surface or diffuses in the microparticles 
(Coombes et al. 1998; Shakesheff et al. 1997). Despite washing prior to lyophilisation, 
it is very difficult to completely remove the PVA coating (Sahoo et a l 2002). In the 
case of PVA added to the internal aqueous phase, it is reasonable to expect that PVA 
also coats the inner cavities and/or pore exits within the polymer matrix. Other groups 
have also suggested that PVA chains penetrate the PLGA matrix (Boury et al. 1995). 
This will be discussed further in relation to DSC data. While DVS data cannot predict 
the extent of PVA penetration throughout the PLGA matrix, a homogenous 
distribution of PVA within PLGA seemed unlikely given their respective physical 
properties. Ultimately, the total amount of PVA remaining on/in the microspheres only 
increased water uptake at high relative humidities.
In contrast, Triton X-100 appeared to increase the hydrophilicity of the 
microspheres more readily, with a change in mass for these microspheres being around
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4% at 95% relative humidity (cf. the corresponding percent change in mass for 
microspheres containing PVA and Flil9'-10, Fm9'-10, and blank microspheres, of 2, 
1.5, and 1.5%, respectively). The small molecular size of Triton X-100 (625 Da) 
compared to PVA may enable its greater infiltration of the PLGA network. Moreover, 
the PEO headgroup of Triton X-100 is known to be miscible with PLGA (Chung et al. 
2002). It would not be surprising then that the washing steps did not completely 
remove the surfactant.
The mode of water vapour-microsphere interaction was revealed by the 
hysteresis for loss of mass in response to decreasing relative humidity. Microspheres 
containing no surfactant showed almost no hysteresis (Fig. 5.1 and Table 5.2). It can 
be argued that water diffusion and mobility in the amorphous PLGA is dependent on 
the water-PLGA interaction. At low humidity, the water-PLGA interaction is expected 
to be high, hence a low mobility of the water molecules. As humidity increases, the 
water affinity towards the amorphous PLGA decreases, eventually changing to a 
water-vapour interaction favouring water mobility. At this point, the hydration limit of 
the polymer is reached (Lechuga-Ballesteros et al. 2003; Oksanen & Zografi 1993). 
The subsequent water vapour-microsphere interaction is accompanied with hysteresis 
as visualised by the difference between the sorption and desorption cycles. The data 
showed that the hydration limit stood between 47% and 71% relative humidity for 
microspheres containing PVA and F1119'-10, and between 23% and 47% relative 













0.00 0.02 0.02 -0.07 -0.01
23.80 0.02 0.00 -0.03 -0.03
47.50 -0.02 0.00 -0.09 -0.29
71.30 -0.06 0.00 -0.18 -0.37
95.00 0.00 0.00 0.00 0.00
Table 5.2. Difference between the gain and the loss of mass for the microsphere 
formulations during sorption and desorption cycles.
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Finally, upon exposure to 95% relative humidity, SEM micrographs showed 
irreversible aggregation of the microspheres (Fig. 5.2). Particle cluster could result 
from binding of surface protein or the formation of interparticulate bridges. The latter 
case would imply a high degree of molecular mobility of the PLGA chains. 
Presumably, a high adsorbance of water at the microspheres surface caused the PLGA 
chains of neighbouring particles to aggregate. The resulting clusters were not free- 
flowing, as necessary for pharmaceutical criteria or intravenous administration. 
Therefore, the relative humidity for controlled surface remodelling without 
microsphere aggregation was thought to be around 75%.
Figure 5.2. SEM images o f microspheres containing FIII9'-10 and Triton X-100 at 
magnification o f 45x  (A) and 300x  (B) upon storing at 93% relative humidity fo r  24 
hours.
5.3.3 Thermal characteristics of the microspheres
The thermal properties of amorphous microspheres reflect the mobility among 
PLGA chains (Hancock et al. 1997; Pozuelo & Baselga 2002). As a result of solvent 
removal and lyophilisation, the polymeric chains are immobilised while trying to reach 
equilibrium (Sertsou et al. 2003). A glassy state is entered when the molecular 
mobility is so slow that the material is kinetically unable to fully relax (Hancock & 
Zografi 1997). Nevertheless, depending on the formulation and the storage conditions,
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ageing may occur where the physical properties continue to change slowly with time as 
the polymer tends to thermal equilibrium with its surroundings (De & Robinson 2004; 
Van den Mooter et a l 1999). Any modification in the structure could therefore be 
detected and characterised using DSC (Mandal et al. 2002a; Mandal et a l  2002b; 
Royall et a l 1998). The period of storage used in these studies was 2 weeks, guided by 
the rapid absorbance of water vapour observed by DVS.
The effect of the storage history on the Tg and glass transition profile of the 
microspheres upon ambient and 75% relative humidity are shown in Fig. 5.3 and 
summarised in Table 5.3. All Tg values are relative to the experimental conditions 
used here and every precaution was taken during sample preparation to minimise 
variation in sample weight and heating rate. As expected, a difference was measured 
between blank and protein- or surfactant-loaded microspheres. Clearly, addition of 
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Figure 5.3. Total DSC heating thermograms over the glass transition region for
microspheres, with and without protein and surfactant, stored fo r  2 weeks at ambient
humidity (AH) (solid lines), and at 75% relative humidity (RH) (dotted lines).
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Alone, the FIII9'-10 protein acted as an antiplasticizing agent, raising the Tg of 
the polymer (cf. the respective Tgo values in Table 5.3). This result may in itself be 
surprising given the weight ratio of protein to PLGA. A tentative explanation of the 
data may involve unfolded and folded fractions of the protein. During emulsification, 
the protein is likely to be denatured, unfolded and aggregated as reported in numerous 
studies (Perez et al. 2002; Sah 1999a). The unfolded protein fraction is left insoluble, 
non-covalently aggregated within the polymeric matrix, whereas the folded protein 
fraction, being soluble, leaves the microsphere during the burst release phase since it is 
only loosely associated with the inner cavities of the microsphere. It is possible that 
PLGA preferentially interacts with one protein form over an other. The protein fraction 
interacting with the PLGA was therefore likely to be the already exposed unfolded 
fraction. Thus, PLGA may interact with the unfolded protein fraction via van der 
Waals forces, reducing polymer chain mobility. This interpretation is consistent with 
other related work (Sanchez 1992; Yamakawa et al 1992), though further validation 





T g o C  C)
Ambient humidity 
24 hours 2 weeks 
A T g j=  A Tg2=  
Tg24h - Tgo Tg2w - Tgo
75% relative humidity 
24 hours 2 weeks 
A T g} = A T g2=  
Tg24h - Tgo Tg2w ~ Tgo
Blank microspheres 27.6 +0.8 +1.4 +1.1 +0.2
Fm9'-10 29.9 -1.7 -1.0 -1.5 -1.9
Fm9'-10 & PVA 29.2 -0.1 +0.9 -1.0 -0.0
Fm9'-10 & Triton 
X-100
20.1 +5.7 +4.3 +2.8 +1.4
Table 5.3. Evolution of the (onset) Tg of microspheres stored at ambient humidity and 
75% relative humidity over time. Microspheres analysed immediately after 
lyophilisation served as references (Tgo) against measurements obtained after 24 
hours (Tgi) and 2 weeks (Tg2) -  shown as the change to the Tg.
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The DSC data showed that addition of PVA to the primary emulsion raised the 
Tg of the resultant microspheres, whereas Triton X-100 dramatically reduced the Tg 
(cf. the respective Tgo values in Table 5.3). It would be difficult to unambiguously 
define the intermolecular interactions occurring between the surfactants and PLGA 
(Shamblin et al 1996). However, the role of surfactant penetration within the PLGA 
matrix was likely to be involved given the known miscibility of the PEO headgroup of 
Triton X-100 with PLGA (Chung et a l 2002). This was consistent with the noticeable 
broadening of the FH[9'-10 and Triton X-100 curve in the region of the glass transition 
as illustrated in Fig. 5.3. Consequently, Triton X-100 may have increased the free 
volume within the entangled PLGA chains, facilitating diffusion of water and PLGA 
molecular mobility, acting as a plasticizer. Conversely, PVA appeared to only weakly 
influence the molecular mobility (or free volume) of the PLGA. The PVA molecules 
tended towards an antiplasticizing effect since small increases to the Tg values were 
observed between microspheres encapsulating F1119'-10 and microspheres 
encapsulating FIII9'-10 with PVA.
The change in Tg upon storage at ambient and elevated humidity revealed 
interesting behaviour. For blank microspheres stored at ambient humidity, the Tg 
increased rapidly within the first 24 hours, with relatively little change thereafter 
(Table 5.3). The increase in the Tg may have been a result of local molecular 
rearrangements (P-relaxations) occurring in any free spaces available as the polymer 
tended toward thermal equilibrium. The increased density would give rise to 
mechanical loss, which, under these circumstances, is known as physical ageing. This 
phenomenon is commonly seen for glasses frozen in non-equilibrium conformation 
due to reduced mobility upon vitrification (Chartoff 1997; Cowie & Ferguson 1986). 
Concomitant with the increase in Tg is the “overheating peak” (enthalpy relaxation) 
observed at the glass transition. This point will be addressed in the following section.
For blank microspheres stored at 75% relative humidity, a similar ageing was 
observed within the first 24 hours; but after 2 weeks the Tg had almost returned to its 
initial value. This could be expected given the uptake of water vapour at the higher 
humidity and the resultant plasticization effect on the PLGA. For microspheres 
containing PVA, the decrease in the Tg at 75% relative humidity versus ambient 
humidity was also consistent with the plasticizing effect of adsorbed water which 
increased the molecular mobility of PLGA (Hancock & Zografi 1994; Oksanen &
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Zografi 1990). The drop in the Tg for microspheres containing only protein and stored 
at high humidity was only apparent after 2 weeks. This suggested that protein was a 
poor mediator of water uptake in comparison to surfactant, which was borne out in the 
DVS data. These analyses showed that the Tg of the microspheres was dependent upon 
the balance between the kinetics of physical ageing versus water-induced 
plasticization.
5.3.4 Analyses of the Enthalpy Relaxation
As expected, when the microspheres were quench cooled following the first 
heating cycle and their thermal behaviour analysed over a second identical cycle, the 
overheating peak almost disappeared given the minimal potential for relaxation (Fig. 
5.4). The overheating peak superposed on the Tg may be confused with an endotherm 
corresponding to the fusion temperature but, crucially, the distinguishing feature is that 
the baseline does not return to its original level. Comparative DSC data for poly lactic 
acid microspheres showing ageing of poly lactic acid microspheres is provided by 
Passerini and Craig (Passerini & Craig 2001).
The examination of the enthalpy relaxation areas over time confirmed the 
existence of the physical ageing phenomenon suggested previously. Although the 
differences in enthalpy relaxation values are very small, a trend showing the increasing 
magnitude of the relaxation endotherms with increasing storage time can be clearly 
seen in Fig. 5.5 where first heat runs of blank microspheres kept under ambient 
humidity over time are superposed. This variation characterises the progression of 
physical ageing undergone by the copolymer. Such typical evolution was observed in 
the endotherms of all microspheres studied, suggesting that all were ageing over time, 
as Figure 5.6 illustrates.
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Figure 5.4. Thermograms o f microspheres kept at ambient humidity fo r  2 weeks 
illustrating the thermal response o f the polymer before (1st heat run) and after (2nd 
heat run) quench cooling.
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Figure 5.5. Evolution o f the enthalpy relaxation o f blank microspheres left at ambient 
humidity with increasing storage time fo r  freshly made microspheres (solid line), and 












However, the curve magnitudes summarised in Table 5.4 differed noticeably in 
accordance with particle’s formulations. Microspheres incorporating Triton X-100 
showed physical ageing, with a rise in the Tg following storage either at ambient 
humidity or 75% relative humidity (Table 5.3). However, their overheating peak was 
relatively small in comparison to PVA and protein-loaded microspheres (Table 5.4). 
This suggested that physical ageing was relatively little, presumably involving 
minimal local PLGA rearrangements. Since Triton X-100 was strongly plasticizing by 
increasing the free volume, the PLGA may have instead tended toward large molecular 
rearrangements involving entire chains (a-relaxations). Further, this high degree of 
molecular mobility could have been facilitated by water sorption (cf. DVS data and the 
increase in Tg following storage at 75% relative humidity). The resultant plasticization 
dominated the thermal characteristics of the microspheres containing Triton X-100.
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Figure 5.6. Raising enthalpy relaxations with increasing ageing time for microspheres 








24 hours 2 weeks
AH24h-AH0 AH2m, - AH0
(J/g) (J/g)
75 % relative humidity 
24 hours 2 weeks 
AH24h - AH0 AH2w - AH0 
(J/g) (J/g)
Blank microspheres -1.33 -1.05 -2.26 -1.01 -1.43
Fni9'-10 -1.69 -0.11 -1.68 -0.54 -1.53
FIII9-10 & PVA -1.22 -0.71 -2.19 -0.90 -1.74
Fm9'-10 & Triton X-100 -0.53 -0.81 -0.63 +0.28 +0.14
Table 5.4. Progression o f the enthalpy relaxation o f microspheres stored at ambient 
humidity and 75% relative humidity over time. Microspheres freshly made served as 
references (AHo) against measurements obtained after 24 hours (AH24h) and 2 weeks 
(AH2m,).
It is likely that the plasticization experienced by ail other microspheres 
subjected to elevated humidity competed with ageing. For all microspheres maintained 
at 75% relative humidity, the relaxation endotherms progressed to a lesser degree than 
for samples stored at ambient humidity after 2 ageing weeks. Unlike microspheres 
formulated with Triton X-100, it was not possible to determine clearly which of the 
plasticizing or the ageing effect was predominant. However, considering that the 
enthalpy relaxations as well as the Tg of the microspheres evolved to higher values, the 
PLGA may have tended toward ageing more than plasticizing. Given the evidence for 
significant molecular rearrangement of the PLGA chains, it was anticipated that 
associated changes to the microspheres’ surface morphology may be observed.
5.3.5 Microsphere surface analyses
SEM analysis o f the microspheres before and after exposure to 75% relative 
humidity showed a general smoothing of the microsphere surface (Fig. 5.7). To further 
investigate the effects of moisture on the morphological properties o f the 
microspheres, AFM was used with a resolution far beyond the capacity o f an SEM.
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Figure 5.7. SEM images of microspheres containing FI 119'-10 and Triton X-100, 
immediately after lyophilisation (A), and stored for 24 hours at 75% relative humidity
(B).
A representative AFM image of the porous structure of a microsphere 
(containing FIII9-10 and PVA) at ambient humidity is shown in Fig. 5.8. The 
topographical image highlights the significant variance in the size and diameters of the 
pores o f the microspheres which were not observable via SEM imaging.
X S. 0 0 0  UM/4 iv 
2  3 . 0 0 0  im/4 iv
Figure 5.8. Representative topography of the surface o f a microsphere containing 
FI 119'-10 and PVA, recorded using the AFM contact mode at ambient humidity.
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In order to examine the direct influence of increasing relative humidity on pore 
stability, individual pores of the microparticles were directly imaged while varying the 
relative humidity. The high resolution AFM images showed subtle remodelling to the 
pore structure of all microspheres (Fig. 5.9), but only microspheres containing FIH9- 
10 and Triton X-100 showed alteration of the pore depth as seen in Fig. 5.10. Cross- 
sectional analysis of the external dimensions of the selected pore in Fig. 5.10 for 
increasing relative humidity is summarised in Table 5.5. It is immediately clear that 
pore depth was markedly reduced as the relative humidity was increased from 55% to 
75%. The modification of this pore’s structure may be related to the increased chain 
mobility of the polymeric matrix associated with the decrease in the Tg, as suggested 
by the DSC data. Thus, as the relative humidity increased, the plasticizing effect of the 
water vapour facilitated chain mobility (the Tg tending towards the experimental, 
room, temperature). However, plasticization of the PLGA matrix was clearly not 
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Figure 5.9. Evolution of the surface topography view from above (A), and from an 
angle o f 45° (B) for microspheres containing FIII9'-10 alone, or with PVA and Triton 
X-100 as indicated. The particles were exposed to relative humidity increasing in steps 
from 20%, to 40%, 55% and 70% relative humidity (RH).
Further analysis o f the pore’s profile (Fig. 5.10) also showed a progressive 
increase in the diameter of the pore upon increasing the relative humidity between 25%
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and 75%. This increase in pore diameter may indicate a degree of swelling of the 
microsphere associated with the absorption of water within the matrix (Sharp et a l
2001). However, the increasing diameter may in part be due to the very shallow slope 
at ca. 4.5 pm across and relative positioning of the X-Y plane.
Previously, it has been reported that collapse of the microsphere surface 
(complete pore closure) was due to internal modifications when microspheres were 
incubated in solution (Ali et a l 1993). It would be interesting to further investigate the 
effect of PLGA molecular weight on the process observed, since Tg is related to chain 
length. Here, for example, the PLGA used had a low MW and Tg which may have 
been favourable to the rapid remodelling process observed, yet the chains were long 
enough to resist a complete collapse of the structure.
It is clear that the remodelling process seen in Fig. 5.10 required a degree of 
plasticity from the PLGA matrix, which presumably caused the associated surface 
changes observed by SEM. Whether internal changes ensued from exposure to 
humidity was not known, although it was strongly expected to take place. By 
understanding moisture effects on the Tg of the matrix, chain mobility and surface 
structure, it may be possible to controllably modify the surface properties of the PLGA 
microspheres for controlled release while conserving a structural integrity. Since pore 
closure is known to be concomitant with attenuation of burst release (Wang et a l
2002), and microspheres with limited exit pores show first order rate release (Ehtezazi 
et a l 2000), it was considered here that reduction of external pore’s depth via high 
humidity may facilitate similar control over drug release. This behaviour was 
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Figure 5.10. AFM topography of a surface pore for a microsphere containing FIII9'- 
10 and Triton X-100 under ambient humidity at 20°C. A cross-section along the line
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marked X-Y revealed the modification of the pore ’s profile under relative humidity of
25% (A), 40% (B), 55% (C), and 75% (D).





Table 5.5. Diameter and depth of the surface pore imaged in Figure 5.10.
5.3.6 Protein distribution in microspheres exposed 
to high humidity
The DVS data indicated that when the microspheres are above their hydration 
limit, water-vapour interactions are induced, which in turn facilitate water mobility 
(Oksanen & Zografi 1993). Under these circumstances, it was reasonable to assume 
that the dynamic activity of the water molecules could have obvious implications for 
protein redistribution within the microspheres. Following this concern, FITC-labelled 
protein was encapsulated and the microspheres were examined by CLSM after 
exposure to 93% relative humidity for 1 and 24 hours. Such high humidity was 
employed in order to ensure a clear recognition of the potential protein rearrangement. 
The difficulty of irreversible aggregation observed in Fig 5.2 was resolved by 
spreading evenly the microspheres on a slide before storage at 93% relative humidity. 
This method resulted in a particularly accurate examination of the microparticles as the 
same slides were used for imaging before and after exposure to high humidity.
The images shown in Fig. 5.11 revealed that the protein did not participate in 
any evident reorganisation. The water-vapour mobility may have been unable to 
support the circulation of the protein around the cavities or outside the microsphere as 
liquid water can do. In the latter case, water is known to be responsible for drug flow 
which inevitably leads to drug extraction due to osmotic pressure. While a continuous
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environment such as liquid water or buffer imposes osmotic differences, it is most 
probable that air nearly saturated with water-vapour molecules could not maintain 
conditions consistent enough to properly generate osmotic pressure. The absence of 
osmotic differences apparently confined the proteins to their original position.




Figure 5.11. Representative images o f FITC-labelled FIII9'-10 distributed throughout 
microspheres (-100 pm  diameter) after fabrication (Time 0), and after 1 and 24 hours 
storage at 93% relative humidity.
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5.3.7 In vitro protein release
Microspheres formulated with F1119'-10 alone and with PVA or Triton X-100 
were stored for 24 h at 75% relative humidity before incubation as this humidity would 
allow for surface remodelling while conserving the free-flowability of the particles. 
The primary emulsion was found to be best stabilised with Triton X-100 yielding the 
highest encapsulation efficiencies for the FIH9'-10. Accordingly, the absolute 
concentrations of protein released in vitro over the 12 weeks period was greatest for 
microspheres prepared with Triton X-100 (Table 5.6).
For all the microsphere formulations, it is interesting to note that, for 
incubation at 37°C, the PLGA matrix of the microspheres will have existed in a 
rubbery state (the Tg being < 37°C, Table 5.3). This is accompanied by an increase in 
chain mobility, facilitating the diffusivity of both the escaping drug and the penetrating 
water (Friess & Schlapp 2002). The in vitro protein release profiles of all microspheres 
showed a typical burst release (Fig. 5.12 A-C), with at least 30% of the protein 
encapsulated released within the first hour. However, the extent of release within the 
first hour was dependent on the formulation and, especially, the storage at ambient 
humidity or high humidity prior to immersion in aqueous buffer. At ambient humidity, 
for microspheres prepared with either F1U9'-10, or FIll9'-10 and Triton X-100 in the 
primary emulsion, above 80% of the encapsulated protein was released within the first 
hour with comparatively little subsequent release. For the same microsphere 
formulations stored at 75% relative humidity, the burst release was significantly 
attenuated and a large proportion of the protein was released in a secondary phase 
occurring at the 4-8 week period. This was particularly noticeable for the microspheres 
prepared with Triton X-100, which were observed to undergo pore reduction at 75% 
relative humidity. The strong attenuation of the burst release is very likely to be related 
to surface pore modification, although a first order release was not observed as may 
have been expected from a previous study (Ehtezazi et al. 2000). The reason for this 
may have been that the number of pores in this study remained the same, albeit 
partially closed, whereas Ehtezazi et al. prepared microspheres with minimal numbers 
of surface pores (Ehtezazi et al. 2000).
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Also, in the case of microspheres containing F1119'-10 and Triton X-100, the 
second burst recorded after 8 weeks was equivalent in terms of protein release to the 
primary release phase (Fig. 5.12 B). Occurrence of a secondary release phase at around 
8-weeks is accountable to erosion of the PLGA matrix. However, the secondary 
release phase seen here is unusually rapid (given the logarithmic scale) and, 
remodelling of the internal pores upon exposure to high humidity was suspected. 
Remodelling of the internal matrix could be expected because the movement of a water 
molecule within PLGA matrix is rapid (Batycky et al. 1997), and would be enhanced 
by the hydrophilic nature of Triton X-100. This large secondary release may have been 
due to ‘temporary storage’ of protein within the remodelled microsphere which 
otherwise have escaped, under ambient humidity, in the burst release (Fig. 5.12 B). In 
effect, protein reservoirs were entrapped within the microsphere, with little protein 
actually entangled with the PLGA matrix.
These release data also corroborate the strong plasticizing effect induced by 
Triton X-100, and the smaller attenuation of the burst release for microspheres 
containing no surfactant in the primary emulsion suggested minimal PLGA 
plasticization. This was further consistent with the observation that addition of the 
antiplasticizer (PVA) to the primary emulsion did not attenuate the burst release 















Ambient humidity 21.91 13.64 38.44
75% relative humidity 18.35 17.60 33.85
Encapsulation efficiencies 
(± S.D.)
13.2% (±4.5%) 23.0% (± 12.9%) 48.2% (± 17.2%)
Table 5.6. Encapsulation efficiency and total protein concentrations released from 

























Figure 5.12. In vitro FIII9'-10 release from microspheres first maintained at ambient 
humidity (n) or at 75% relative humidity (o) for 24 hours, and then immersed in PBS 
over 12 weeks, at 37°C. The data are normalised to the cumulative protein 
concentration at 12 weeks. A, microspheres prepared without surfactant in the primary 
emulsion; B, microspheres prepared with Triton X-100 added to the primary emulsion; 
C, microspheres prepared with PVA in the primary emulsion.
5.4 Conclusions
Residual PVA and Triton X-100 were found to increase the hydrophilicity of 
the resultant microspheres. Triton X-100 had a strong plasticizing effect on the PLGA 
matrix with an associated increase in the free volume. In contrast, PVA and 
encapsulated protein acted as antiplasticizing agents. The mechanical properties of 
surfactant free microspheres were influenced by the environmental humidity. At 
ambient humidity, PLGA chain reorganization resulted in a denser matrix and 
increased the Tg, whereas at 75% relative humidity, the plasticizing effect of water 
vapour was observed by depression of the Tg. AFM imaging demonstrated that the 
PLGA surface is amenable to remodelling upon exposure to elevated conditions of 
relative humidity (> 75% RH), with a tendency towards surface smoothing and pore 
closure. This is consistent with previous work by Wang et al. showing complete pore 
closure upon microsphere immersion in aqueous buffer (Wang et al. 2002). Despite the 
reduction in pore depth facilitated by water vapour-induced plasticization, complete 
pore collapse was not observed. Remodelling of pores in this manner for microspheres 
containing FIII9'-10 with Triton X-100 halved the burst release. The accompanying 
secondary release being of equal magnitude and rate, suggested remodelling of the 
internal porous matrix. Therefore, depending on the stability of the drug encapsulated, 
brief exposure of PLGA microspheres to high humidities may prove to be an effective 




Examination of the mechanical 
properties of PLGA microspheres
6.1 Introduction
Recent thermodynamic analysis of PLGA microparticles has yielded important 
information concerning their mechanical properties and how they may be related to 
stability during storage, drug encapsulation and release (Friess & Schlapp 2002; Zhang 
et al. 2003). Ideally, the mechanical state of the polymeric microspheres should remain 
stable and facilitate an appropriate drug release.
The work here aimed to characterise the material properties of the PLGA 
microparticles by thermodynamic measurements using DSC. Two different chain 
lengths of PLGA were selected to fabricate microparticles, and their mechanical 
integrity was evaluated under various conditions. The influence of protein size and 
structure, as well as the effect of freeze-drying versus drying under a stream of dry 
nitrogen gas on PLGA microspheres was assessed. Finally, the polymeric particles 
were exposed to different storage conditions over three months and their physical state
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was subsequently evaluated. Unfortunately, further investigation of PLGA mechanical 
properties could not be pursued due to time limitations.
6.2 M ethods
6.2.1 Lysozyme microencapsulation
Lysozyme was loaded without surfactant into PLGA microspheres following 
the emulsion evaporation process described previously (Chapter 2.3.1). Briefly, an 
inner aqueous phase of 95 pi of lysozyme at 20 mg/ml in PBS was incorporated to 950 
pi of DCM with PLGA (5% w/v), and homogenised at 22000 rpm for 15 seconds (IKA 
Ultra Turrax T18). This primary emulsion was transferred into 40 ml of water with 
PVA (0.5% w/v) and stirred at 500 rpm for 2 h at room temperature to allow for 
solvent evaporation and capsides hardening. The particles were collected, dried and 
stored as described in Chapter 2.3.1.
6.2.2 Fabrication and drying of microspheres
Blank microspheres were fabricated with low molecular weight PLGA (15,000 
g/mol), or high molecular weight PLGA (135,000 g/mol). Microspheres were dried 
following either the freeze-drying process described in section 2.3.1, or the drying 
process using nitrogen gas during thermogravimetric (TGA) analysis. For the latter, 
microspheres suspended in a minimal volume of water were placed in an aluminium 
pan and positioned on a sensitive microbalance assembly (TGA/SDT A822e, Mettler 
Toledo). Dry nitrogen gas circulated over the pan while maintaining a temperature of 
25°C. Under these conditions, water evaporated from the sample causing a change in 
mass which was recorded by the TGA apparatus. The sample was considered to be 
fully dried when no further change in mass was observed. The physical properties were 
quantified by DSC immediately after completion of drying, and the data were analysed 
against the unprocessed PLGA of respective molecular weight.
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6.2.3 Storage of the microspheres over three 
months
The effects of storage over three months were studied on blank microspheres, 
microspheres made with FIH9'-10 and PVA or Triton X-100, and microspheres made 
without FH[9'-10 but containing the same fraction of PVA or Triton X-100 (5 pi) 
added to the inner water phase of the primary emulsion. The latter particles were 
termed as ‘blank and PVA’ and ‘blank and Triton X-100’. Low and high molecular 
weight PLGAs were used to fabricate each type of microparticle.
Microspheres were first analysed immediately after lyophilisation by DSC. 
Then, each batch of microspheres was divided into two Eppendorf tubes, sealed tightly 
with Parafilm, and placed under different storage conditions for three months. One 
batch was kept under ambient conditions, that is, at ambient temperature (~20°C) and 
ambient humidity (-23% relative humidity). The other was placed in a sealed box with 
fresh silica gel (replaced as necessary) and stored in a fridge (~4°C). After three 
months, the microspheres were analysed by DSC.
6.3 Results and discussion
6.3.1 Influence of the nature of the encapsulated 
drug
Lysozyme is a small globular protein (ca. 14 kDa) with four disulphide bonds 
and therefore relatively rigid. This is in contrast to Fm9'-10 which is a p-sandwich 
domain pair (ca. 20 kDa) with no disulphide bonds. The two proteins were 
encapsulated in low molecular weight PLGA (ca. 15000 MW) without addition of 
surfactant to the primary emulsion. The microspheres’ thermodynamic characteristics 
were measured after freeze-drying and compared to blank microparticles. The Tg and
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enthalpy relaxation measurements of blank microspheres and microspheres loaded 
with H 119'-10 and lysozyme are summarised in Table 6.1.
While F1U9-10 acted as an antiplasticizer increasing the Tg, lysozyme did not 
cause any change to the Tg compared to blank microspheres. Enthalpy relaxation 
values suggested that the ageing of PLGA was more pronounced for encapsulation of 
lysozyme, although additional experimentation should be pursued to confirm the 
variations. Differences between the Tg and enthalpy relaxation values for FUI9-10 and 
lysozyme may reflect protein specific interactions with the PLGA chains. While this 
could be accounted to the different secondary and tertiary structures, these data do not 
provide unambiguous evidence for this.
Microspheres formulation Tg (°C) AfiT(J/g)
Blank microspheres 27.6 -1.3
Microspheres with FILL9'-10 29.7 -1.7
Microspheres with lysozyme 27.5 -2.4
Table 6.1. Measurements of the Tg and enthalpy relaxation o f microspheres containing 
either FIII9'-10 or lysozyme, and compared against blank microspheres.
Van der Waals forces have been identified as the main form of interaction 
between protein and polymer, in some cases retaining the protein within the structure 
during in vitro release (Jiang et a l 2002). The extent of the protein/polymer 
interactions is also known to depend on electrostatic, double layer forces. A study by 
Blanco and Alonso demonstrated that lysozyme (pKa 9.2 and therefore basic) 
exhibited particularly high interactions with the acidic PLGA chains (pKa 3.8), 
whereas BSA (pKa 5.6) had a much lower affinity towards the polymer (Blanco & 
Alonso 1998). Presumably, lysozyme and FI1I9-10 lodged within the polymeric 
microspheres here were both subjected to these intermolecular forces.
Proteins are known to unfold and aggregate during encapsulation, and it has 
been previously suggested the same for Flll9'-10. It would have been interesting to 
compare what predominantly acts for folded/unfolded protein fractions and how they 
may affect Tg and polymer ageing. However, time limitations and the anticipated 
complexity of such experiment prevented further study.
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6.3.2 Effects of the drying process on the stability 
of PLGA
Two drying techniques were selected and tested on blank microspheres in order 
to evaluate the effects of removal of bulk water on PLGA stability. Freeze-drying, 
which generally eliminates bulk and bound water, was chosen and compared to drying 
using dry nitrogen gas at 25°C with monitoring of drying by thermogravimetric (TGA) 
analysis. The Tg and enthalpy relaxation of raw polymers and dried microspheres were 
computed and summarised below.
Low MW PLGA High MW PLGA
Tg (°C) AH( J/g) Tg (°C) AH (J/g)
Unprocessed PLGA 30.2 -3.8 43.2 -5.1
Blank microspheres freeze-dried 27.6 -1.3 38.4 -4.2
Blank microspheres air-dried 28.0 -1.3 40.6 -5.4
Table 6.2. Physical properties of freeze-dried and nitrogen-dried microspheres 
compared against unprocessed polymer. Low and high molecular weight PLGA were 
used to manufacture blank microspheres.
As expected, the Tg for the high molecular weight PLGA was greater than for 
the low molecular weight PLGA and corresponded to the manufacturing data 
(Birmingham polymers, UK). It was also noted that unprocessed PLGA of both low 
and high molecular weights had higher Tg values than the corresponding microspheres. 
It follows that PLGA chains in the microsphere have a greater degree of disorder than 
the unprocessed PLGA. This observation is in accordance with work published by 
Sandor et al., showing that rapid PLGA precipitation during solvent extraction 
immobilised the polymeric chains into a highly dispersed configuration (Sandor et al. 
2002).
For low molecular weight PLGA, no significant change of Tg was observed 
when comparing the two different drying techniques, whereas high molecular weight
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PLGA microspheres dried by lyophilisation had a lower Tg than when air-dried. The 
latter could be attributed to more complete removal of bulk water. In effect, Passerini 
et al. examined oil-in-water microparticles and found incomplete water removal after 
lyophilisation (Passerini & Craig 2001). It follows that the content of residual water 
was greater for the lyophilisation process than air-drying. However, it seemed unlikely 
that the plasticization from residual water would cause such a decrease in Tg and 
enthalpy relaxation of the freeze-dried particles made with high molecular weight 
PLGA. It may be the case that lyophilisation physically changed the PLGA matrix. 
Kim et al. reported that upon snap-freezing, the volume fraction of ice expands such 
that voids were left behind once the water had been sublimed (Kim & Park 2004b). 
The gain in free-volume would logically facilitate chain mobility, and so lower the Tg 
of the lyophilised microparticles, beyond that seen by air-drying.
6.3.3 Stability over different storage conditions for 
3 months
Drug delivery vehicles must preserve the therapeutic activity of the 
encapsulated drug during storage. To achieve this, the integrity of the carrier is 
important. For amorphous polymers such as PLGA, physical ageing is associated with 
minor chain relaxation (side-group rotations) (Ford & Timmins 1989). Storage at 
temperatures near the polymer Tg value are expected to increase the rate of ageing, this 
being of particular consideration for low molecular weight PLGA (Tg ~ room 
temperature). Furthermore, surfactant and drug encapsulated may act as plasticizers. 
Since glassy and rubbery states affect drug release and PLGA degradation, it is 
important to characterise the change in Tg and enthalpy relaxation during microsphere 
storage.
Data for microspheres stored three months under ambient or cold and dry 
conditions are presented in Table 6.3. The glass transition of blank microspheres 
increased over three months regardless of storage conditions and was associated with 
greater ageing. Microspheres formulated with high molecular weight PLGA and with 
F1119'-10 and Triton X-100 showed a large decrease in three months storage 
irrespective of storage condition. It is interesting to note that this is in contrast with the
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same formulation but with low molecular weight PLGA where large rises in Tg were 
observed. The difference is difficult to explain, but may reflect the different extent of 
influence from Triton X-100 (plasticizing) and FJLU9'-10 (antiplasticizing) on high and 
low molecular weight PLGA during storage. Overall, the majority of the microspheres 
demonstrated typical profiles of physical ageing. However, noticeable differences 
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3 months 3 months 
under under cold 
ambient and dry 
conditions conditions
ATgAc = ATgcD -  
TgAC - Tgo TgcD - Tgo
Blank microspheres 27.6 +2.0 +1.8 38.4 +3.2 +4.3
Blank & PVA 27.2 +2.4 +2.9 37.8 +3.9 +5.3
FED’-IO & PVA 29.2 +1.4 -0.4 39.6 +0.7 +1.4
Blank & Triton X- 
100
26.4 -2.1 +1.5 33.5 +2.1 +3.5
FUI9-10 & Triton 
X-100
20.1 +6.8 +11.8 41.8 -4.5 -4.8
Table 6.3. Evolution of the (onset) Tg o f microspheres made with low and high 
molecular weight PLGA and stored for three months under ambient or cold and dry 
conditions. Tg values for microspheres analysed immediately after lyophilisation (Tgo) 
served as reference for values obtained after three months under ambient conditions 
(TgAC) and cold and dry conditions (Tgcob Values are shown as the change to the Tg.
The Tg of microspheres fabricated with high molecular weight PLGA varied in 
accordance with the particle formulation, as was expected. However, no significant 
difference was observed with respect to the storage conditions. Only microparticles 
formulated with FIII9'-10 and Triton X-100 had their Tg lowered after three months 
storage, yet again the decrease was identical whether kept under ambient or cold 
conditions. The consistency of the polymer mechanical evolution suggested that 
microspheres made with high molecular weight PLGA could ignore the stresses 
applied by storage parameters. Presumably, the long chains’ need for equilibrium
142
would overcome the environmental conditions and initiate small chain relaxations, 
characteristic of physical ageing. The differences of ageing progressions between 
batches may originate in varying formulation parameters.
Microspheres fabricated with low molecular weight PLGA demonstrated 
stronger fluctuations within batches and storage conditions, although in some cases the 
changes may have been within the margin of sensitivity of the DSC (for example, 
microspheres containing FH19'-10 and PVA). For example, particles fabricated with 
Triton X-100 alone showed an increase in the Tg when kept under cold and dry 
conditions, but under ambient conditions showed a decrease in the Tg. These variations 
suggested that the mechanical integrity of short PLGA chains was harder to maintain 
and to predict over time. Influenced by the environment and the formulation 
parameters, short polymeric chains may not be able to sustain the phenomenon of 
physical ageing in a consistent manner.
It is. also interesting to note that the plasticizing and antiplasticizing natures of 
Triton X-100 and PVA, respectively, were revealed mostly when FJil9'-10 was 
encapsulated together with the surfactants. This may be caused by the 
protein/surf actant interaction which might hinder the extraction of surfactant molecules 
during the wash. Greater residual amounts of surfactant within the structure would then 
alter more severely the conversion of the polymeric chains from free rotation, when 
dissolved into the solvent, to inactivity when precipitated.
6.4 Conclusions
PLGA microspheres were analysed under different conditions in order to 
understand what modulates the polymer mechanical integrity and ideally, what could 
improve it. Protein/polymer interactions were found to alter the polymer chains in 
microspheres made with low molecular weight PLGA. However, supplementary work 
would be necessary to determine which of the folded or unfolded protein fraction is 
more susceptible to induce structural perturbations. Drying under nitrogen gas was 
found to be a more acceptable drying technique as it allowed for a greater repossession 
of the PLGA thermo-equilibrium than lyophilisation. Besides, air-drying does not
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require detrimental steps such as snap-freezing. The difference between lyophilising 
and air-drying was particularly evident for microspheres made with high molecular 
weight PLGA which also differed from low molecular weight PLGA during storage. 
After three months storage, all microspheres made with high molecular weight PLGA 
had consistently aged regardless of the formulation parameters. On the contrary, the 
mechanical activity of microspheres containing low molecular weight PLGA was 
dependent on the formulations parameters. It follows that long PLGA chains are more 
consistent over time than short polymer chains which are more easily influenced and 





This thesis focused on the encapsulation of FJLLL9-10 in PLGA microspheres 
fabricated with non-ionic surfactants added to the primary emulsion of the w/o/w 
emulsion-evaporation technique. Pluronic F68, Tween 20, Tween 80, Triton X-100 
and Igepal CA-630, were selected as alternatives to model stabilisers such as PVA and 
BSA. Innovative analytical devices and techniques were designed in order to assess the 
viability of the novel microspheres and to gain an insight into protein and particles 
characteristics.
The integrity and level of biological activity of the integrin-binding Fm9'-10 
were tested on protein released from incubated microspheres. SDS-PAGE analysis 
showed that the protein backbone was consistently preserved throughout microsphere 
fabrication. More importantly, FIII9'-10 released after 3 hour incubation promoted cell 
attachment in a concentration-dependent manner, as desired. Therefore, the biological 
activity of FIII9'-10 was proven unaltered, and the microencapsulation of a 
conformationally labile protein, an encouraging prospect. Meanwhile, the evaluation of 
the protein’s vehicle indicated that several features of the microspheres had been 
affected by the emulsifiers added to the primary emulsion. These features listed below 
are fundamental to drug delivery systems:
♦ encapsulation efficiency
♦ protein release profile





♦ hydrophilic properties of the microspheres
♦ thermodynamic properties of PLGA
The performance variations among batches were assigned to the underlying 
molecular interactions between surfactant and drug/PLGA. Unfortunately, it was not 
possible to unambiguously define the nature of these molecular interactions, and only 
their impact on the particles could be determined accurately. In some cases, these 
interactions were detrimental to the drug delivery system. For example, a 
multivesicular structure or a microcapsule would be formed with Pluronic F68, Tween 
20, Tween 80, or Igepal CA-630. These results implied that these surfactants were
unable to resist stresses such as solvent extraction or polymer precipitation during the
secondary emulsification. Also, the encapsulation efficiency was overall not 
significantly improved, unless Triton X-100 or Igepal CA-630 was used. However, the 
common feature shared by all microspheres was the initial burst release which was 
further inspected.
Real-time CLSM helped to visualise the liberation of soluble and mobile 
protein through exit pores of microspheres in static immersion. Meanwhile, cryo- 
fracture SEM revealing the particles’ internal structure indicated that the initial burst 
release mechanism was unrelated to the inner matrix morphology. Therefore, it was 
concluded that the accessibility to the release medium was the predominant factor 
inducing burst release. However, despite the small number and size of pores on surface 
of particles made with Pluronic F68, Tween 20, Tween 80, Triton X-100 or Igepal CA- 
630, the porosity appeared to be still sufficient to allow for the initial burst release to 
proceed. It follows that further reduction in external porosity is necessary to attain an 
ideal zero-order drug release. In order to fulfil this objective, a new approach based on 
the mechanical properties of amorphous PLGA was studied and discussed.
The potential of PLGA molecular rearrangement was originally revealed by 
SEM images of incubated microspheres showing surface smoothing and external pore 
disappearance. The persistent and rapid changes of the particles’ external morphology 
were attributed to the high molecular mobility initiated and sustained by the elevated 
temperature as well as the plasticizing effect of water. Surface remodelling via 
molecular rearrangement was therefore considered as a prospective method to reduce
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surface porosity of selected microparticles. Microspheres made with FIII9'-10 and 
Triton X-100 were chosen for their high encapsulation efficiency and initial low 
surface porosity. Microspheres made with FIII9'-10 and PVA were used as a reference. 
The hydrophilic properties of the particles were first examined by DVS. It was found 
that the residual amount of Triton X-100 greatly enhanced the microspheres’ 
hydrophilicity. Effectively, the small size of Triton X-100 molecules and their known 
miscibility with PLGA allowed for their infiltration in between PLGA chains. 
Therefore, additional free-volume was created and made available not only for water- 
vapour penetration, but also for side-group rotations of PLGA chains. Residual Triton 
X-100 molecules were also attributed the plasticizing effect responsible for reducing 
the Tg of the amorphous microspheres. This plasticization was advantageously used to 
further the molecular mobility in PLGA microspheres exposed to 75% relative 
humidity. It was anticipated that high level of molecular motion would promote 
surface remodelling to the point of pore closure which, ultimately, would be a major 
obstacle for protein release. In effect, not only the initial burst was significantly 
attenuated, but a second burst was also recorded after 8 weeks incubation probably as a 
result of internal remodelling.
Finally, further evaluation of the polymeric chain stability conducted over three 
months confirmed the stronger consistency of long PLGA chains over shorter ones. 
Also, it was found that the weaker mechanical integrity of short PLGA chains would 
benefit from less detrimental formulation parameters such as air-drying as opposed to 
freeze-drying. However, further research is necessary to offer a consistent 
understanding of PLGA mechanical behaviour.
Suggested future work
Over the course of this thesis, the role of PLGA mechanical properties was 
emphasised. Exposure to 75% relative humidity was proven an effective method to 
reduce the initial burst release. In order to conclusively verify this method, the 
integrity of the protein should be assessed again. As the initial burst release was 
influenced by the thermodynamic characteristics of the PLGA matrix, it is reasonable
148
to wonder if the rate of protein release is also dependent on the mechanical state of 
PLGA chains. The answer to that question could be deduced from a comparative 
analysis of the molecular mobility of particles made with low and high molecular 
weight PLGA against the drug release profile. If molecular activity and drug release 
increase concurrently, it may be the case that drug mobility is facilitated by side-group 
rotations of adjacent PLGA chains. In fact, the same could apply to the extraction of 
polymeric degradation products during polymer erosion. Additional analysis of 
microspheres’ Tg and enthalpy relaxation over incubation time should be compared 
against mass and molecular weight loss of the polymeric microspheres.
Also, the molecular interactions between surfactant and drug/PLGA should be 
carefully examined as they have been proven to change the local environment of the 
drug. Although these interactions might affect the PLGA, more importantly they are 
generally detrimental to the protein. In effect, the protein conformation is often 
disturbed due to protein adsorption at the water/oil interface, even in the presence of 
stabilisers. It is important to understand the reasons why stabilisers may fail to protect 
the protein from irreversible damage. Causes such as competitive adsorption between 
drug and stabiliser at the water/oil interface should be expected and examined along 
with electrostatic interactions. Ideally, a thorough understanding of the molecular 
interactions between surfactant and drug/PLGA may help in explaining the relative 
easiness of microencapsulation of certain drugs over others.
Finally, extended work could focus on external and internal morphologies of 
particles in order to clearly determine the correlation between external porosity and 
initial burst release. Batches of microspheres characterised by a range of external 
porosity should be examined and their release profiles recorded. Analysis of the 
specific surface area and the average pore radius might also bring additional 
information. Ultimately, it would be interesting to analyse the internal morphology of 
microspheres during in vitro testing. Given the results obtained on microspheres 
exposed to high humidity, it would be advantageous to determine the link between 
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